

Deciphering anti-infectious compounds from Peruvian medicinal *Cordoncillos* extract library through multiplexed assays and chemical profiling

Pedro G. Vásquez-Ocmín^{1†*}; Sandrine Cojean^{2,3*}; Vincent Roumy^{4*}; Guillaume Marti^{5,6}; Sébastien Pomel²; Alice Gadea¹; Karine Leblanc²; Indira Dennemont²; Liliana Ruiz-Vásquez^{7,8}; Hivelli Ricopa Cotrina⁸; Wilfredo Ruiz Mesia⁹; Stéphane Bertani^{1,10}; Lastenia Ruiz Mesia^{8,9,1}; Alexandre Maciuk^{2*,1}

[†]Curent affiliation: Laboratoire de Recherche en Sciences Végétales (UMR 5546), CNRS, Université de Toulouse, Toulouse, France.

^{*}These authors contributed equally to this work

¹These authors share senior authorship

¹UMR152 PHARMADEV, IRD, UPS, Université de Toulouse, Toulouse, France

²Université Paris-Saclay, CNRS, BioCIS, 91400, Orsay, France

³CNR du Paludisme, AP-HP, Hôpital Bichat - Claude Bernard, F-75018 Paris, France

⁴Joint Research Unit 1158 BioEcoAgro, Univ. Lille, JUNIA, INRAE, Univ. Liège, UPJV, Univ. Artois, ULCO, F-59650, Villeneuve d'Ascq, France

⁵Laboratoire de Recherche en Sciences Végétales (UMR 5546), CNRS, Université de Toulouse, Toulouse, France

⁶MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, France

⁷Facultad de Farmacia y Bioquímica, Universidad Nacional de la Amazonía Peruana (UNAP), Iquitos 16000, Peru

⁸Centro de Investigación de Recursos Naturales, Universidad Nacional de la Amazonía Peruana (UNAP), Iquitos 16002, Peru

⁹Facultad de Ingeniería Química, Universidad Nacional de la Amazonía Peruana (UNAP), Iquitos 16002, Peru

¹⁰International Joint Laboratory of Molecular Anthropological Oncology (LOAM), National Cancer Institute, Lima, Perú

* Correspondence:

Pedro G. Vásquez-Ocmín

vasco2224@gmail.com

Alexandre Maciuk

alexandre.maciuk@universite-paris-saclay.fr

Abstract

High prevalence of parasitic or bacterial infectious diseases in some world areas is due to multiple reasons, including a lack of an appropriate health policy, challenging logistics and poverty. The support to research and development of new medicines to fight infectious diseases is one of the sustainable development goals promoted by World Health Organization (WHO). In this sense, the traditional medicinal knowledge substantiated by ethnopharmacology is a valuable starting point for drug discovery. This work aims at the scientific validation of the traditional use of *Piper* species (“*Cordoncillos*”) as firsthand anti-infectious medicines. For this purpose, we adapted a computational statistical model to correlate the LCMS chemical profiles of 54 extracts from 19 *Piper* species to their

corresponding anti-infectious assay results based on 37 microbial or parasites strains. We mainly identified two groups of bioactive compounds (called features as they are considered at the analytical level and are not formally isolated). Group 1 is composed of 11 features being highly correlated to an inhibiting activity on 21 bacteria (principally Gram-positive strains), one fungus (*C. albicans*), and one parasite (*Trypanosoma brucei gambiense*). The group 2 is composed of 9 features having a clear selectivity on *Leishmania* (all strains, both axenic and intramacrophagic). Bioactive features in group 1 were identified principally in the extracts of *Piper strigosum* and *P. xanthostachyum*. In group 2, bioactive features were distributed in the extracts of 14 *Piper* species. This multiplexed approach provided a broad picture of the metabolome as well as a map of compounds putatively associated to bioactivity. To our knowledge, the implementation of this type of metabolomics tools aimed at identifying bioactive compounds has not been used so far.

Keywords: Anti-infectious diseases, *Cordoncillos*, metabolomics, Peruvian Amazonia, *Piper*

55 INTRODUCTION

56 In Amazonia, tropical diseases have a high prevalence due to multiple reasons, including a lack of an
 57 appropriate health policy, a climate conducive to diseases, challenging logistics and poverty. Neglected
 58 tropical diseases (NTDs) are a group of 20 conditions (caused by viruses, protozoa, helminths and
 59 bacteria) prioritized by the World Health Organization (WHO). The NTDs are responsible for
 60 approximately 200,000 deaths and the loss of 19 million disability-adjusted life years (DALYs)
 61 annually. In 2020, new infections by *Plasmodium* spp. and *Leishmania* spp. worldwide were estimated
 62 at 241 and 1 million, respectively. Even if *Plasmodium* is not strictly classified as a NTD, it caused
 63 around 627,000 deaths in 2020, with two-thirds of these deaths (470,000) being due to treatment
 64 disruptions during the COVID-19 pandemic (WHO, 2021). *Leishmania* spp. and *Trypanosoma* spp.
 65 are protozoan parasites responsible of diseases labeled as NTDs *stricto sensu*. The ambitious 10-year
 66 WHO plan to defeat NTDs is based on three pillars: control, elimination and eradication (WHO,
 67 2022a). The support of research and development of new medicines to fight infectious diseases is one
 68 of the sustainable development goals promoted by WHO (WHO, 2022b). Drug resistance is a
 69 widespread concern in medical care, and the increase of drug-resistant infections is faster than the pace
 70 of the development of new drugs approved for use in humans. Therefore, every input into the search
 71 for new antimicrobial agents is welcome (Yan et al., 2021). Ethnopharmacology is the interdisciplinary
 72 study of the knowledge or practices of traditional cultures related to plants, animals, or mineral used
 73 for therapeutic purposes (SFE, 2022). Such knowledge can be valued as the starting point for drug
 74 discovery, especially in the case of infectious diseases which are prevalent among such populations.

75 Piperaceae is a pantropical family composed of eight genera. Two genera are the most representative
 76 in this family: *Piper* and *Peperomia* (Vásquez-Ocmín et al., 2017; Salehi et al., 2019). Among these,
 77 *Piper* is the most diverse and representative genus, encompassing *ca.* 2600 species (Trujillo et al.,
 78 2022). Besides pungent compounds, many *Piper* species produce essential oils and are hence highly
 79 aromatic, explaining their use for cooking and medicinal purposes (Ruiz-Vásquez et al., 2022). In Peru,
 80 *Piper* spp. (called “Cordoncillos”) have been used for a very long time in traditional medicine as a
 81 “first-hand treatment”, especially in the villages far away from major cities and medical care. The
 82 necessary scientific validation of traditional uses implies the isolation of the main bioactive compounds
 83 by successive fractionations using chromatographic techniques and biological activity testing (bio-
 84 guided isolation). Such an approach has evidenced interesting activities for *Piper* spp. as anti-
 85 inflammatory, antiparasitic, antibacterial, etc. (Mgbeahurike et al., 2017; Durant-Archibold et al.,
 86 2018). Even if bio-guided fractionation is still used with some success in the natural product chemistry
 87 field, current trends involve streamlining the cost, effort, and time (Vásquez-Ocmín et al., 2022a).
 88 Metabolomics is a holistic approach allowing rapid detection and putative identification (*i.e.*
 89 annotation) of numerous metabolites, along with data mining on multiple datasets. Metabolomics aims
 90 to comprehensively map all biochemical reactions in a given system and has become a key to
 91 deciphering their biological roles, hence becoming mainstream in natural product chemistry and drug
 92 discovery. This approach can be divided into targeted and untargeted analyses (Alarcon-Barrera et al.,
 93 2022). Two spectral techniques are regularly employed for metabolomics analysis: mass spectrometry
 94 (MS) and nuclear magnetic resonance (NMR) spectroscopy, both being assisted by bioinformatics and
 95 statistical analysis. Our team has solid expertise in implementing straightforward and effective
 96 workflows to decipher anti-infectious compounds using untargeted metabolomics (Vásquez-Ocmín et
 97 al., 2021a).

98 This work aims at the scientific validation of the use of *Piper* species as firsthand anti-infectious
 99 medicines. We adapted a statistical model to correlate the LCMS chemical profiles of 54 extracts from
 100 19 *Piper* species to their corresponding anti-infectious assay results based on 37 microbial or parasites
 101 strains. This multiplexed approach led to the annotation of compounds bearing these activities.

MATERIALS AND METHODS

Ethnopharmacology and Plant Material

Based on the encouraging previous results of our research group on the anti-infectious activities of *Piper* species (Vásquez-Ocmín et al., 2021a), ethnopharmacological surveys were realized as part of the project “Compuestos bioactivos *in vitro* a partir de especies vegetales Amazónicas”. The surveys were undertaken between July and December 2020 in communities of three Amazonian regions of Peru: Cusco, Loreto and San Martín. People of these communities were interrogated about the main use of medicinal *Piper* species (“*Cordoncillos*”), including their use against malaria, “uta” (local name for leishmaniasis) and bacteria. According to ethnopharmacological studies, we collected 8 species in Cusco, 10 species in Loreto, and 1 species in San Martín.

Thus, different parts of these nineteen plants were collected, then identified and deposited in the Herbarium Amazonense (AMAZ), Iquitos, Peru. This project was realized in accordance with the guidelines pertaining to ethnopharmacological studies and edited by the Laboratorio de Investigación de Productos Naturales Antiparasitarios de la Amazonia (LIPNAA) of the Universidad Nacional de la Amazonia Peruana (UNAP) (Resolución Rectoral N° 1312-2020-UNAP).

Preparation of plant extracts

One hundred grams of each air-dried and ground plant (leaves, leaves and stems, aerial parts) were soaked in 1 L of each of the following solvents successively: hexane, methylene chloride, methanol, ethanol/water (7:3 v/v), and aqueous. Extractions were made for 21 days for hexane, methylene chloride and ethanol/water, and for 15 days in methanol and aqueous extracts, with solvents being changed every 3 days. The extracts were then filtered through a paper filter and evaporated under reduced pressure below 40°C. Dry extracts were stored at -4 °C until use. Extracts were solubilized in DMSO at a concentration of 10 mg/mL for *in vitro* bioassays and HPLC-MS analysis.

Cell lines and microorganism culture

HUVEC cells: Human umbilical vein endothelial cells (HUVECs) were maintained in culture in RPMI 1640 medium (Invitrogen, Life Technologies) supplemented with 10 % heat-inactivated fetal bovine serum (Invitrogen Life Technologies) and 1 mM glutamine (Invitrogen Life Technologies) (Vásquez-Ocmín et al., 2018).

RAW264.7: The mouse monocyte/macrophage cell line RAW264.7 was maintained in culture in DMEM (Invitrogen, Life Technologies) supplemented with 10 % heat-inactivated fetal bovine serum (Vásquez-Ocmín et al., 2018).

Plasmodium: The *P. falciparum* chloroquine-sensitive strain 3D7 was obtained from the Malaria French National Reference Center (CNR Paludisme, Hôpital Bichat Claude Bernard, Paris) and was maintained in O⁺ human erythrocytes in RPMI 1640 medium (Invitrogen, Life Technologies) supplemented with 25 mM HEPES (Sigma), 25 mM NaHCO₃ (Sigma) and 0.5 % Albumax II (Invitrogen, Life Technologies) at 37°C in a candle-jar method following the Trager and Jensen conditions (Trager and Jensen, 1976; Lambros and Vanderberg, 1979; Vásquez-Ocmín et al., 2018).

Leishmania: The *L. donovani* MHOM/ET/67/HU3, *L. amazonensis* MHOM/BR/73/M2269, and *L. braziliensis* MHOM/BR/75/M2903b strains were maintained routinely in *in vitro* culture. Passages in macrophages RAW 264.7 were carried out regularly to preserve the virulence of the strain, then they were recovered for culture maintenance in the promastigote form. For assays, parasites were

maintained as promastigote forms in M-199 medium (Sigma) supplemented with 40 mM HEPES, 100 mM adenosine, 0.5 mg/L hemin and 10 % fetal bovine serum (FBS) at 25°C in a dark environment (Balaraman et al., 2015; Vásquez-Ocmín et al., 2018).

Trypanosomes: Trypomastigotes of *T. b. gambiense* (FéoITMAP/1893 strain) were grown in HMI9 medium constituted of prepacked Iscove's modified Dulbecco's medium (Thermo-Fisher, Les Ulis, France) supplemented with 36 mM NaHCO₃, 1 mM hypoxanthine, 0.05 mM bathocuproine, 0.16 mM thymidine, 0.2 mM 2-mercapthoethanol, 1.5 mM L-cysteine, 10 % heat-inactivated foetal bovine serum, 100 IU penicillin and 100 µg.mL⁻¹ streptomycin. Parasites were incubated in a Series 8000 direct-heat CO₂ incubator (Thermo-Fisher, Les Ulis, France) at 37°C in a water-saturated atmosphere containing 5 % CO₂ (Pomel et al., 2015; Vásquez-Ocmín et al., 2018).

Bacteria and yeast:

Most microbial strains were diluted in BH medium (Brain Heart), MH medium (Mueller Hinton) for *Candida sp.* and *Mycobacterium sp.*, or WW medium (Wilkins-West) for *Streptococcus sp.* and stored at -20°C. Then strains were subcultured at 20°C on RC (Ringer Cysteine) medium for 24 hours before tests (Bocquet et al., 2019).

***In vitro* antiprotozoal activity**

In vitro antiplasmodial activity on *P. falciparum*

Assays were realized with a suspension of erythrocytes at 1 % parasitemia containing more than 85 % ring stage obtained by repeated sorbitol treatment and incubated with the compounds at concentrations ranging between 0.49 and 100 µM or µg/mL, obtained by serial dilution, in duplicates. Two controls were used, parasites without drug and parasites with chloroquine at concentrations ranging between 0.49 and 1000 nM. Plates were incubated for 44 h at 37 °C in a candle jar (Vásquez-Ocmín et al., 2018, 2021a).

In vitro antileishmanial activity on *L. donovani*, *L. amazonensis*, and *L. braziliensis* axenic amastigotes

A suspension of promastigotes in growth plateau-phase was incubated at 37°C in 5 % CO₂ for 3 days to obtain the amastigote form in promastigote medium supplemented with 2 mM CaCl₂, 2 mM MgCl₂, and a pH adjusted to 5.5. The axenic amastigote suspension containing 1.106 parasites/mL was incubated for 72h with the compounds at 37°C in 5 % CO₂ in the dark. Tested compounds or extracts were obtained by serial dilution and ranged between 0.49 and 100 µM or µg/mL. There were two controls: parasites without drug and parasites treated with miltefosine at the same concentrations as the compounds tested (Vásquez-Ocmín et al., 2018, 2021a).

In vitro antileishmanial activity on *L. donovani*, *L. amazonensis* and *L. braziliensis* intramacrophage amastigote form

Macrophages were seeded into a 96 well microtitration plate at a density of 100,000 cells/well in 100 µL and incubated in a 5 % CO₂ at 37°C for 24h. After removing the medium, cells were incubated with 100 µL of fresh DMEM containing a suspension of promastigotes in the growth plateau phase at a rate of 1 cell per 10 parasites. After incubation under a 5 % CO₂ atmosphere at 37°C for 24h (the time needed by the parasite to infect the macrophage), the culture medium was replaced with 100 µL of fresh DMEM with different concentrations of compounds as previously for a new incubation period of 48h. Controls were parasites alone in DMEM medium, axenic amastigotes, macrophages alone, infected macrophages and infected macrophages with different concentrations of miltefosine (Balaraman et al., 2015; Vásquez-Ocmín et al., 2018, 2021a).

Determination of IC_{50} , CC_{50} and Selectivity Index for *Plasmodium*, *Leishmania*, and *Trypanosoma*

After incubation, the plates were subjected to 3 freeze/thaw cycles to achieve complete cell lysis. The cell lysis suspension was diluted 1:1 except for *Plasmodium* plates that have been diluted 1:10 in lysis buffer (10 mM NaCl, 1 mM Tris HCl pH 8, 2.5 mM EDTA pH 8, 0.05 % SDS, 0.01 mg/mL proteinase K and 1X SYBR Green). SYBR Green incorporation in cell DNA amplification was determined using the Master epRealplex cycler® (Eppendorf, France) and the following program to increase SYBR Green incorporation: 90°C for 1 min, decrease in temperature from 90°C to 10°C for 5 min with fluorescence reading at 10°C for 1 min and a new reading at 10°C for 2 min. Molecules were tested in duplicate. Compounds with different SYBR Green fluorescence values from duplicates were retested. The cytotoxicity of the compounds was expressed as IC_{50} (concentration of drug inhibiting the parasite growth by 50 %, comparatively to the controls), CC_{50} (Cytotoxic Concentration 50 %: concentration inhibiting macrophages growth by 50 %). IC_{50} and CC_{50} were calculated by nonlinear regression using ICEstimator 1.2 version (<http://www.antimalarial-icestimator.net/MethodIntro.htm>). Selectivity index (SI) for antiplasmodial and anti-*Trypanosoma* activities were calculated as the HUVEC's CC_{50} divided to IC_{50} of *Plasmodium* 3D7 and *Trypanosoma*, and for *Leishmania* assays as the ratio of RAW 364.7 CC_{50} to intramacrophage amastigote IC_{50} value (Vásquez-Ocmín et al., 2018, 2021a).

In vitro evaluation on bloodstream form of *Trypanosoma brucei gambiense*

For each extract, twelve two-fold serial dilutions from 100 µg/mL to 0.049 µg/mL were performed in 96-well microplates in 100 µL HMI9 medium. Parasites were then added to each well to reach a final density of 4.104 cells/mL in 200 µL. Following 3 days of incubation at 37°C with 5 % CO_2 in a water-saturated atmosphere, 20 µL of resazurin at 450 µM in water was added to each well for a final concentration of 40.9 nM to evaluate cell viability. Plates were then incubated for 6h at 37°C with 5 % CO_2 in water-saturated atmosphere and the conversion of resazurin to resorufin was quantified by measuring the absorbance at 570 nm (resorufin) and 600 nm (resazurin) using the microplate reader Spark® (Lyon, France) Pentamidine di-isethionate was used as the reference compound (Pomel et al., 2015; Vásquez-Ocmín et al., 2018, 2021a).

Antimicrobial Assay

Minimal Inhibitory Concentration (MIC) determinations of crude extracts were carried out using the agar dilution method stipulated by the Clinical and Laboratory Standards Institute (CLSI, 2006). Antimicrobial activity was evaluated for the first time against a panel of 36 pathogenic and multi-drug-resistant bacteria, which, in most cases, have been recently isolated from human infections. For comparison, reference strains from the American Type Culture Collection (ATCC) were included. The inhibitory concentrations ranged between 0.075 and 1.2 mg/mL in five dilutions (1.2, 0.6, 0.3, 0.15 and 0.075 mg/mL); 0.075 mg/mL was considered a low enough concentration for a preliminary screening. Petri dishes were inoculated with strains (104 CFU, obtained by dilution in brain heart medium, BH) using a Steer's replicator and were incubated at 37°C for 24 h. MIC was defined as the lowest concentration of extract without bacterial growth after incubation. The extracts with $MIC \leq 1.2$ mg/mL were tested in triplicate at lower concentrations (mean absolute deviation is done for values: 1.2 ± 0.4 ; 0.6 ± 0.2 ; 0.3 ± 0.1 ; 0.15 ± 0.05 ; 0.075 ± 0.03). The standards (gentamicin, vancomycin, amoxicillin, amphotericin B, fluconazole, and sertaconazole) were tested in triplicate in 12 concentrations ranging from 0.03 to 64 mg/mL.

Cytotoxic assay

Cytotoxicity was evaluated on RAW 264.7 macrophages for *Leishmania* assays and HUVECs for *Plasmodium* and *Trypanosoma*. The cells were seeded at a density of 50,000 cells per well in 100 μ l of DMEM in a 96-well microtiter plate. After incubation in a 5 % CO₂ at 37°C for 24h, the culture medium was replaced with 100 μ l of fresh DMEM containing serial dilutions of the compounds tested. The concentrations of the compounds are the same as for intramacrophage *Leishmania* or *Plasmodium* assays. The plates were incubated for 48h at 37°C with 5 % CO₂. Antiprotozoal assays have been performed only with compounds not demonstrating cytotoxicity (Vásquez-Ocmín et al., 2021a).

Liquid chromatography and mass spectrometry data mining

HPLC-MS analyses

Extracts were analyzed by liquid chromatography performed on an Agilent 1260 series HPLC coupled to a 6530 QToF (Agilent Technologies). Chromatography separations were performed on a XSelect column C18, 2.1 x 75 mm – 2.5 μ m (Waters). The mobile phase comprised water (0.1 % formic acid) (A) and acetonitrile (ACN) (B). A stepwise gradient method at a constant flow rate of 0.35 mL/min was applied as follows: 5–100% B (0–9.5 min), 100% B (4.5 min) and 4 min equilibration at 5% B. The mass spectrometer settings were: positive ESI mode, 50–3200 mass range calibration, and 2 GHz acquisition rate. Ionization source conditions were drying gas temperature 325 °C, drying gas flow rate 10 L/min, nebulizer 35 psig, fragmentor 150 V, and skimmer 65 V. Range of m/z was 200–1700. Purine C₅H₄N₄ [M+H]⁺ ion (m/z 121.050873) and the hexakis-(1H,1H,3H-tetrafluoropropoxy)-phosphazene C₁₈H₁₈F₂₄N₃O₆P₃ [M+H]⁺ ion (m/z 922.009798) were used as internal lock masses. Full scans were acquired at a resolution of 11 000 (at m/z 922). MS-MS acquisitions were performed using three collision energies: 10, 20, and 40 eV. Three of the most intense ions (top 3) per cycle were selected. MS-MS acquisition parameters were defined as follows: m/z range 100–1200, default charge of 1, minimum intensity of 5000 counts, rate/time = 3 spectra/s, isolation width: Narrow (1.3 u).

Data processing

For untargeted metabolomics, the LC-MS data were processed according to the MSCleanR workflow (Fraisier-Vannier et al., 2020; Vásquez-Ocmín et al., 2021b). Briefly, a batch in positive ionization (PI) was processed with MS-DIAL version 4.90 (Tsugawa et al., 2015). MS1 and MS2 tolerances were set to 0.01 and 0.05 Da, respectively, in centroid mode for each dataset. Peaks were aligned on a QC reference with an RT tolerance of 0.2 min, a mass tolerance of 0.015 Da, and a minimum peak height detection at 1×10^5 . MS-DIAL data was deconvoluted together with MS-CleanR by selecting all filters with a minimum blank ratio set to 0.8 and a maximum relative standard deviation (RSD) set to 40. The maximum mass difference for feature relationship detection was set to 0.005 Da, and the maximum RT difference was set to 0.025 min. Pearson correlation links were used with a correlation ≥ 0.8 and a p-value significance threshold of 0.05. Two peaks were kept in each cluster for further database requests and the kept features were annotated with MS-FINDER version 3.52 (Tsugawa et al., 2016). The MS1 and MS2 tolerances were set to 5 and 15 ppm, respectively. The formula finder was exclusively based on C, H, O, and N atoms. Three levels of compounds annotation from several sets of data were carried out. Metabolite annotation at level 1 using MS-DIAL: i) the experimental LC-MS/MS data of 500 compounds (retention time, exact mass and fragmentation) were used as references; ii) the Mass spectral records from MS-DIAL, MONA (MassBank of North America), and GNPS (Global Natural Product Social Molecular Networking) databases were used for spectral match applying a dot product score cut-off of 800. Metabolite annotation at level 2 was prioritized according to: i) a search would be made using MSFinder for a match with compounds identified in the literature for the *Piper* genus (genus level) and Piperaceae family (family level) (Dictionary of Natural Products version 28.2, CRC Press) based on exact mass and *in silico* fragmentation. For metabolite annotation

level 3, a search was made using MS-FINDER for a match with natural compounds included in their databases embedded (PlantCyc, ChEBI, NNPDB, COCONUT, and KNApSack) (generic level) (Vásquez-Ocmín et al., 2022b).

Mass spectra similarity networking was carried out from PI mode using MetGem (Olivon et al., 2018) on the final annotated .msp file and metadata file for PI obtained with MSCleanR. Values used were MS2 m/z tolerance = 0.02 Da, minimum matched peaks = 4 and minimal cosine score value = 0.7. The visualization of the molecular network (MN) was performed on Cytoscape version 3.9.1 (Shannon et al., 2003). The list of compound mass, retention time, row ID and peak height was exported in CSV format. Then, this format was used for the statistical data analysis.

Statistical analyses

The final annotated untargeted metabolome feature matrix and biological assay results datasets were analyzed using the R package MixOmics (<http://mixomics.org/>), which is dedicated to the integrative analysis of ‘omics’ data (Le Cao et al., 2016). Biological assays results expressed in IC₅₀ were transformed in pIC₅₀ (-log₁₀ [IC₅₀]) for further statistical correlation analysis. MIC values were log transformed. The LC-MS dataset (*m/z* × RT × peak area) was normalized to total ion chromatogram and scaled to unit variance. A vertical integration approach has been afforded to leverage on multiplexed measurements for the same extract (González et al., 2008). To highlight the overall correlation between chemical fingerprints and biological assays results, a regularized Canonical Correlation Analysis (rCCA) was done using a cross validation approach for tuning regularization parameters. The correlation structure of the two-block data matrices was displayed on clustered image map (CIM) and relevance network using 0.3 as cutoff correlation value.

RESULTS

Ethnopharmacological survey

Our set of 19 samples was collected in three Amazonian regions of Peru, where the use of these species of “*Cordoncillos*” in traditional medicine is widespread. All information about the collected samples are presented in **supp info 1**. Among the plants studied in this work, 10 (52.6 %) had not been subject to chemical analysis so far. In our previous work (Vásquez-Ocmín et al., 2021a), *Piper casapiense*, *P. strigosum* and *P. pseudoarborescens* showed promising antiprotozoal activity. Thus, these plants were re-collected in other areas of the Loreto region.

Anti-infectious activity

Antiprotozoal activity

The IC₅₀ values for antiplasmodial, antileishmanial and antitrypanosomal activities of each extract are shown in **Table 1**. We considered an extract active and worthy to be further studied when its IC₅₀ value was below 10 µg/mL. Four extracts were active in this case regarding the 3D7 *P. falciparum* chloroquine-sensitive strain assay: the hexane and methylene chloride extracts of *P. crassinervium*, the methanol extract of *P. stellipilum*, and the methylene chloride extract of *P. xanthostachyum*. Only the methylene chloride extracts of *P. crassinervium*, and *P. oblongum* were active on three strains of *Leishmania* (both axenic and intra-macrophagic amastigotes). For the other active extracts, six were not active on intra-macrophagic forms: hexane and methylene chloride of *P. heterophyllum*, hexane, methylene chloride and water extracts of *P. sancti-felices* (*L. amazonensis*) and a hexane extract of *P. crassinervium* (*L. donovani*). Hexane extract of *P. “cordatomentosa”* was active on all the strains, both axenic and intramacrophagic amastigotes, except on axenic amastigote forms of *L. donovani*. Five

314 extracts were active only on *L. amazonensis*, and *L. braziliensis* (both axenic and intramacrophagic
 315 amastigotes): methylene chloride extracts of *P. calvescentinerve*, *Piper crassinervium*, and *P.*
 316 *oblongum*, and the methylene chloride and hexane extracts of *Piper "cordatomentosa"*, and *Piper*
 317 *crassinervium*. Five extracts were active only on *L. donovani*, and *L. braziliensis* (both axenic and
 318 intramacrophagic amastigotes), the methylene chloride extract of *P. crassinervium*, and the hexane and
 319 methylene chloride extracts of *P. heterophyllum*, and *P. oblongum*. Hexane extract of *P. glabribaccum*
 320 was not active on axenic amastigote forms of *L. donovani*. Two extracts were active on *L. donovani*,
 321 and *L. amazonensis*, both forms, methylene chloride extracts of *Piper crassinervium*, and *P.*
 322 *oblongum*. Selective activity on *L. braziliensis* were observed for twelve extracts, the hexane and
 323 methylene chloride extracts *Piper sancti-felicis*, *Piper stellipilum*, and *P. xanthostachyum*; hexane and
 324 methylene chloride extracts of *P. stellipilum*, and hexane and methylene chloride extracts of *P.*
 325 *calvescentinerve* and of *P. divaricatum*. None of the extracts showed selective activity on *L. donovani*
 326 or *L. amazonensis*.

Table 1. *In vitro* antiprotozoal and cytotoxicity activities of *Piper* extracts. M = methanol; H = hexane; D = methylene chloride (D stands for dichloromethane); HA = hydroalcoholic; Aq = aqueous; NT = not tested. *Species showing no reference in phytochemical literature on Web of Science and PubMed. **Extracts previously tested (Vásquez-Ocmín et al., 2021a) (the plants in this work come from different collection site). L = leaves; L&S = Leaves and stems; AP= aerial parts; “” = species with temporary botanical name (these species need more taxonomical studies).

Species, Region (Part tested)	Extract (code for metabolomic analyses)	<i>P. falciparum</i> 3D7 strain, IC ₅₀ ± SD, µg/mL	<i>L. donovani</i> LV9 strain (axenic amastigotes), IC ₅₀ ± SD, µg/mL	<i>L. donovani</i> LV9 strain (intra- macrophagic amastigotes), IC ₅₀ ± SD, µg/mL	<i>L.</i> <i>amazonensis</i> (axenic amastigotes), IC ₅₀ ± SD, µg/mL	<i>L. amazonensis</i> (intra- macrophagic amastigotes), IC ₅₀ ± SD, µg/mL	<i>L. braziliensis</i> (axenic amastigotes), IC ₅₀ ± SD, µg/mL	<i>L. braziliensis</i> (intra- macrophagic amastigotes), IC ₅₀ ± SD, µg/mL	<i>Trypanosoma</i> <i>brucei</i> <i>gambiense</i> IC ₅₀ ± SD, µg/mL	HUVEC CC ₅₀ ± SD, µg/mL	RAW 264.7 macrophages CC ₅₀ ± SD, µg/mL
<i>Piper</i> <i>casapiense</i> (Miq.) C. DC., Loreto (L&S)	H (P4H)	>100	>100	NT	>100	NT	>100	NT	0.68 ± 0.14	>100	>100
	D (P4D)**	>100	>100	NT	>100	NT	>100	NT	4.06 ± 1.11	45.31 ± 1.97	61.12 ± 4.41
	M (P4M)	>100	>100	NT	60.64 ± 6.07	44.22 ± 3.3	>100	NT	18.59 ± 11.62	30.48 ± 2.55	64.88 ± 6.98
<i>Piper strigosum</i> Trel.; Loreto (L&S)	H (P12H)**	>100	>100	NT	74.24 ± 6.33	22.41 ± 3.12	17.41 ± 0.71	9.07 ± 0.22	0.10 ± 0.02	>100	>100
	D (P12D)**	>100	>100	NT	54.43 ± 4.22	31.12 ± 2.66	12.33 ± 0.43	8.12 ± 0.87	0.028 ± 0.004	41.66 ± 4.01	66.01 ± 5.13
	M (P12M)**	>100	>100	NT	54.21 ± 4.32	20.97 ± 2.08	20.22 ± 0.20	17.64 ± 1.64	4.22 ± 1.59	51.22 ± 4.20	>100
<i>Piper</i> <i>pseudoarborescens</i> Yunck; Loreto (L&S)	H (P14H)**	>100	>100	NT	>100	NT	>100	NT	12.06 ± 3.80	61.94 ± 4.64	>100
	D (P14D)**	>100	>100	NT	>100	NT	>100	NT	5.07 ± 2.17	40.21 ± 4.12	>100
	M (P14M)**	>100	>100	NT	>100	NT	>100	NT	28.56 ± 15.97	25.49 ± 1.87	49.09 ± 3.88
* <i>Piper armatum</i> Trel. & Yunck; Loreto (L&S)	H (P18H)	>100	>100	NT	>100	NT	>100	NT	25.04 ± 5.33	>100	>100
	D (P18D)	>100	>100	NT	>100	NT	>100	NT	1.50 ± 0.16	55.31 ± 4.12	>100
	M (P18M)	>100	>100	NT	>100	NT	>100	NT	11.26 ± 1.90	35.86 ± 2.88	33.03 ± 2.99
* <i>Piper</i> <i>brasiliense</i> C. DC; Loreto (L&S)	H (P19H)	>100	>100	NT	23.45 ± 2.74	20.12 ± 1.66	14.20 ± 1.33	12.66 ± 1.64	29.47 ± 12.31	>100	>100
	D (P19D)	20.19 ± 1.44	>100	NT	12.66 ± 1.64	10.22 ± 1.99	18.41 ± 1.84	11.22 ± 1.88	1.11 ± 0.13	20.19 ± 1.44	21.99 ± 2.37
* “ <i>Piper</i> <i>bullatum</i> Vahl”; Cusco (L&S)	H (P20H)	>100	>100	NT	>100	NT	>100	NT	5.05 ± 1.51	>100	77.64 ± 6.88
	D (P20D)	>100	>100	NT	>100	NT	>100	NT	4.40 ± 0.54	43.79 ± 4.41	41.66 ± 3.64
	M (P20M)	>100	>100	NT	>100	NT	>100	NT	21.47 ± 12.60	25.09 ± 2.40	>100
* <i>Piper</i> <i>calvescentinerve</i> Trel; Cusco (L&S)	H (P21H)	>100	29.29 ± 2.12	22.64 ± 2.01	17.44 ± 1.55	15.84 ± 1.11	6.33 ± 0.63	1.92 ± 0.07	3.97 ± 0.25	>100	>100
	D (P21D)	>100	>100	NT	2.55 ± 1.08	1.94 ± 0.84	3.54 ± 0.16	1.64 ± 1.02	6.08 ± 0.49	38.83 ± 5.41	44.88 ± 4.34
	M (P21M)	>100	>100	NT	>100	NT	43.61 ± 3.87	20.64 ± 1.55	17.75 ± 1.32	38.55 ± 1.13	72.22 ± 6.66
<i>Piper</i> "cordatomentos"	H (P22H)	>100	12.41 ± 0.88	9.78 ± 1.55	8.77 ± 1.12	5.66 ± 1.88	6.92 ± 0.71	3.22 ± 0.48	4.50 ± 1.27	>100	>100
	D (P22D)	>100	17.99 ± 0.77	18.34 ± 0.66	10.44 ± 1.45	10.44 ± 1.84	4.59 ± 0.45	1.08 ± 0.33	2.62 ± 1.11	58.32 ± 5.68	61.44 ± 4.11

<i>a''</i> ; Cuzco (L&S)	M (P22M)	>100	>100	NT	>100	NT	>100	NT	34.58 ± 13.10	61.50 ± 2.62	>100
<i>Piper crassinervium</i> Kunth.; Cusco (L&S)	H (P23H)	5.66 ± 0.87	8.05 ± 0.74	>100	8.55 ± 1.61	4.55 ± 1.09	6.48 ± 1.22	3.18 ± 1.08	7.08 ± 0.85	3.51 ± 0.71	10.44 ± 0.79
	D (P23D)	7.41 ± 0.99	2.95 ± 0.32	0.99 ± 1.33	3.18 ± 1.08	2.66 ± 1.88	5.77 ± 1.12	1.25 ± 1.46	3.25 ± 0.62	>100	37.38 ± 4.52
	M (P23M)	>100	>100	NT	>100	NT	2.70 ± 0.19	1.12 ± 1.46	14.44 ± 9.07	15.28 ± 3.07	37.38 ± 4.52
<i>Piper divaricatum</i> G. Mey; San Martin (L)	H (P24H)	>100	>100	NT	>100	NT	>100	NT	4.57 ± 0.94	30.04 ± 4.95	55.95 ± 4.12
	D (P24D)	>100	>100	NT	>100	NT	2.61 ± 0.27	5.44 ± 0.88	4.02 ± 0.39	>100	>100
<i>*Piper glabribaccum</i> Trel; Cusco (L&S)	H (P25H)	>100	12.05 ± 3.25	8.33 ± 1.48	12.44 ± 0.77	11.41 ± 1.61	3.58 ± 0.45	3.88 ± 0.44	4.83 ± 1.36	>100	>100
	D (P25D)	>100	5.04 ± 1.2	10.33 ± 2.10	13.41 ± 0.45	11.22 ± 0.43	3.57 ± 0.45	6.66 ± 0.64	3.85 ± 1.26	35.62 ± 2.54	77.20 ± 6.61
	M (P25M)	>100	>100	NT	>100	NT	>100	NT	14.98 ± 2.75	84.72 ± 1.25	>100
<i>Piper heterophyllum</i> Ruiz & Pav.; Loreto (L)	H (P26H)	>100	4.32 ± 0.76	3.11 ± 0.99	15.66 ± 1.46	11.51 ± 0.98	5.55 ± 0.95	3.15 ± 0.99	17.27 ± 0.59	81.67 ± 2.17	89.66 ± 5.78
	D (P26D)	>100	6.56 ± 0.61	7.0 ± 0.61	10.41 ± 0.64	11.32 ± 1.61	2.07 ± 0.20	3.44 ± 0.88	11.59 ± 3.93	17.14 ± 2.19	50.53 ± 5.11
<i>*Piper oblongum</i> Kunth; Cusco (L&S)	H (P27H)	>100	8.02 ± 1.16	7.66 ± 1.11	13.45 ± 1.99	15.64 ± 1.66	5.03 ± 1.39	4.13 ± 1.22	4.91 ± 0.75	48.32 ± 1.18	51.64 ± 4.30
	D (P27D)	>100	3.70 ± 0.71	1.36 ± 0.88	8.77 ± 1.65	7.44 ± 0.78	3.58 ± 0.43	4.13 ± 0.99	5.94 ± 1.88	26.23 ± 1.01	>100
	M (P27M)	>100	>100	NT	>100	NT	5.03 ± 1.39	5.03 ± 1.40	10.65 ± 2.21	21.43 ± 1.99	77.56 ± 4.81
<i>Piper reticulatum</i> L; Loreto (L)	H (P28H)	>100	>100	NT	>100	NT	>100	NT	11.84 ± 1.29	>100	>100
	D (P28D)	>100	>100	NT	>100	NT	>100	NT	6.65 ± 1.31	>100	84.46 ± 5.88
	M (P28M)	>100	>100	NT	>100	NT	>100	NT	24.92 ± 6.60	>100	77.54 ± 7.12
<i>*Piper sancti-felicitis</i> Trel; Loreto (L&S)	H (P29 H)	>100	17.88 ± 1.11	18.41 ± 1.33	21.55 ± 1.46	18.22 ± 1.62	4.10 ± 0.57	3.44 ± 0.99	6.60 ± 1.24	>100	>100
	D (P29 D)	>100	13.11 ± 0.88	10.45 ± 0.46	18.41 ± 1.34	17.51 ± 1.99	4.21 ± 0.52	6.44 ± 0.99	9.23 ± 2.58	49.40 ± 4.04	>100
	Aq (P29 Aq)	>100	4.63 ± 0.63	1.12 ± 0.77	8.64 ± 0.44	11.51 ± 1.41	6.07 ± 0.16	10.31 ± 0.11	48.13 ± 8.38	72.22 ± 4.98	>100
<i>*Piper stellipilum</i> (Miq.) C. DC; Loreto (L&S)	H (P30H)	>100	>100	NT	>100	NT	3.74 ± 0.65	8.41 ± 1.31	6.78 ± 3.78	>100	>100
	D (P30D)	13.44 ± 0.21	>100	NT	>100	NT	4.45 ± 0.45	9.99 ± 1.34	9.64 ± 0.46	18.05 ± 1.04	66.54 ± 5.12
	M (P30M)	8.22 ± 0.77	>100	NT	>100	NT	12.33 ± 1.08	15.64 ± 1.88	13.15 ± 2.01	25.03 ± 3.09	51.44 ± 2.99
<i>*Piper trigonum</i> C. DC.; Cusco (L&S)	H (P31H)	>100	>100	NT	>100	NT	>100	NT	8.84 ± 0.29	>100	>100
	D (P31D)	>100	>100	NT	>100	NT	>100	NT	4.84 ± 1.40	30.51 ± 3.05	77.45 ± 4.44
	M (P31M)	>100	>100	NT	>100	NT	>100	NT	10.93 ± 2.53	>100	70.67 ± 6.12
<i>*Piper verruculosum</i> C. DC.; Cusco (L&S)	H (P32H)	>100	>100	NT	>100	NT	>100	NT	8.54 ± 2.90	>100	>100
	D (P32D)	>100	>100	NT	>100	NT	>100	NT	5.64 ± 0.41	>100	>100
	M (P32M)	>100	>100	NT	>100	NT	>100	NT	27.38 ± 6.81	>100	>100
<i>Piper xanthostachyum</i> C.DC.; Loreto (L)	H (P33H)	>100	17.54 ± 0.99	11.12 ± 1.01	21.46 ± 1.89	18.44 ± 1.46	6.51 ± 0.64	9.55 ± 0.55	14.00 ± 1.26	>100	>100
	D (P33D)	6.33 ± 0.74	14.79 ± 0.77	15.32 ± 0.99	29.44 ± 1.46	15.63 ± 1.77	2.98 ± 0.29	5.45 ± 0.66	2.25 ± 0.83	6.18 ± 1.74	52.12 ± 4.03
	HA (P33HA)	>100	23.11 ± 1.08	18.47 ± 1.12	30.48 ± 2.66	15.66 ± 1.63	23.88 ± 0.89	21.41 ± 1.48	4.11 ± 0.69	49.84 ± 4.31	45.89 ± 4.08

Chloroquine	0.007 (21.40 ± 1.56 nM)	NT	NT	NT	NT	NT	NT	NT	NT	NT
Miltefosine	NT	1.41 ± 0.50 (3.46 ± 1.22 μM)	2.49 ± 0.45 (6.10 ± 1.10 μM)	1.88 ± 1.39 (4.61 ± 3.41 μM)	2.15 ± 1.78 (5.28 ± 4.37 μM)	3.49 ± 1.85 (8.56 ± 4.54 μM)	2.22 ± 1.64 (5.44 ± 4.02 μM)	NT	NT	NT
Pentamidine	NT	NT	NT	NT	NT	NT	NT	0.006 ± 0.002 (17.6 ± 5.8 nM)	NT	NT

Selectivity index (SI) values for antiprotozoal activities (**Table 2**) were ranked as low $>10<50$, high $>51<99$, and very high >100 . For antimalarial activity, the only active extract displaying a low SI (13.50) was the methylene chloride extract of *P. crassinervium*. For the antileishmanial activity, methylene chloride extract of *P. crassinervium* and hexane extracts of *Piper glabribaccum* and *P. heterophyllum* showed a low SI on *L. donovani* with 37.76, 12.0, and 28.82 respectively; methylene chloride and aqueous extracts of *P. oblongum* and *P. sancti-felicitis* showed high SI with 73.53 and 89.29 respectively. For *L. amazonensis*, three extracts presented a low SI, methylene chloride extracts of *P. "cordatomentosa"*, *P. crassinervium*, and *P. oblongum* with 13.39, 14.05, and 13.44 respectively. For *L. braziliensis*, 17 extracts displayed low SI, the hexane extracts of *P. strigosum*, *P. "cordatomentosa"*, *P. glabribaccum*, *P. heterophyllum*, *P. oblongum*, *P. sancti-felicitis*, *P. stellipilum*, and *P. xanthostachyum* (11.02, 31.06, 25.77, 28.46, 12.50, 29.07, 11.89, 10.47), methylene chloride extracts of *Piper calvescentinerve*, *P. crassinervium*, *P. divaricatum*, *P. glabribaccum*, *P. heterophyllum*, *P. oblongum*, and *P. sancti-felicitis* (27.37, 29.90, 18.38, 11.59, 14.69, 24.21, 15.53, respectively); methanol extracts of *Piper crassinervium*, and *P. oblongum* (33.36 and 15.42). Only the hexane and methylene chloride extracts of *P. calvescentinerve* and *P. "cordatomentosa"* presented a high SI with 52.08 and 56.89, respectively.

At least one extract of all nineteen plants, except *P. heterophyllum*, was active on *T. b. gambiense* at $IC_{50} \leq 10 \mu\text{g/mL}$ (**Table 1**). The only two plants that displayed activity in all extracts were *P. strigosum* and *P. divaricatum*. Among all active extracts, five had very good activity with a $IC_{50} \leq 1 \mu\text{g/mL}$, hexane and methylene chloride extracts of *P. strigosum*, hexane extract of *P. casapiense*, and methylene chloride extracts of *P. armatum*, and *P. brasiliense*. Especially, the methylene chloride extract from *Piper strigosum* was very active with an IC_{50} at $0.028 \mu\text{g/mL}$. Three extracts presented a high SI, hexane extract of *P. casapiense* with 147.06 and the hexane and methylene chloride extracts of *P. strigosum* with 1000 and 1487.86, respectively. Twenty extracts displayed a lower yet interesting SI between 10.58 and 36.87.

Table 2. Selectivity index of *Piper* extracts calculated with CC_{50} on HUVEC cells for *P. falciparum* and *T. b. gambiense*, and CC_{50} on RAW 264.7 cells for *Leishmania* strains. M = methanol; H = hexane; D = methylene chloride (D stands for dichloromethane); Aq = aqueous; ND = not determined. *Species with no phytochemical reference in Web of Science and PubMed. **Extracts previously tested (Vásquez-Ocmín et al., 2021a) (the plants come from different collection site). L = leaves; L&S = Leaves and stems. “” = species with a temporary botanical name (these species need further taxonomic study).

Species	Extract (code for metabolomic analyses)	SI on <i>P. falciparum</i> 3D7 strain, CC_{50}/IC_{50}	SI on <i>L. donovani</i> (intra-macrophagic amastigotes), CC_{50}/IC_{50}	SI on <i>L. amazonensis</i> (intra-macrophagic amastigotes), CC_{50}/IC_{50}	SI on <i>L. braziliensis</i> (intra-macrophagic amastigotes), CC_{50}/IC_{50}	SI on <i>T. b. gambiense</i> , CC_{50}/IC_{50}
<i>Piper casapiense</i>	H (P4H)	≤ 1	ND	ND	ND	147.06
	D (P4D)**	0.45	ND	ND	ND	11.16
	M (P4M)	0.30	ND	1.46	ND	1.64
<i>Piper strigosum</i>	H (P12H)**	≤ 1	ND	4.46	11.02	1000
	D (P12D)**	0.42	ND	2.12	8.13	1487.86
	M (P12M)**	0.51	ND	4.77	5.67	12.14
<i>Piper pseudoarboreum</i>	H (P14H)**	0.62	ND	ND	ND	5.14
	D (P14D)**	0.40	ND	ND	ND	7.93
	M (P14M)**	0.25	ND	ND	ND	0.89

<i>*Piper armatum</i>	H (P18H)	≤ 1	ND	ND	ND	3.99
	D (P18D)	0.55	ND	ND	ND	36.87
	M (P18M)	0.36	ND	ND	ND	11.26
<i>*Piper brasiliense</i>	H (P19H)	≤ 1	ND	4.97	7.90	3.39
	D (P19D)	1.00	ND	2.15	1.96	18.19
<i>*“Piper bullatum”</i>	H (P20H)	≤ 1	ND	ND	ND	19.80
	D (P20D)	0.44	ND	ND	ND	9.95
	M (P20M)	0.25	ND	ND	ND	1.17
<i>Piper calvescentinerve</i>	H (P21H)	≤ 1	4.42	6.31	52.08	25.19
	D (P21D)	0.39	ND	2.31	27.37	6.39
	M (P21M)	0.39	ND	ND	ND	2.17
<i>“Piper cordatomentosa”</i>	H (P22H)	≤ 1	10.22	1.77	31.06	22.22
	D (P22D)	0.58	3.35	13.39	56.89	22.26
	M (P22M)	0.62	ND	ND	ND	1.79
<i>Piper crassinervium Kunth</i>	H (P23H)	0.62	0.10	2.99	3.28	0.50
	D (P23D)	13.50	37.76	14.05	29.90	30.77
	M (P23M)	0.15	ND	ND	33.36	10.58
<i>Piper divaricatum</i>	H (P24H)	0.30	ND	ND	ND	6.57
	D (P24D)	≤ 1	ND	ND	18.38	24.88
<i>*Piper glabribaccum</i>	H (P25H)	≤ 1	12.00	8.76	25.77	20.70
	D (P25D)	0.36	7.47	0.15	11.59	9.25
	M (P25M)	0.85	ND	ND	ND	5.66
<i>Piper heterophyllum</i>	H (P26H)	0.82	28.82	7.79	28.46	4.73
	D (P26D)	0.17	7.22	4.46	14.69	1.48
<i>*Piper oblongum</i>	H (P27H)	0.48	6.74	3.30	12.50	9.84
	D (P27D)	0.26	73.53	13.44	24.21	4.42
	M (P27M)	0.21	ND	ND	15.42	2.01
<i>Piper reticulatum</i>	H (P28H)	≤ 1	ND	ND	ND	8.45
	D (P28D)	≤ 1	ND	ND	ND	15.04
	M (P28M)	≤ 1	ND	ND	ND	4.01
<i>*Piper sancti-felicis</i>	H (P29 H)	≤ 1	5.13	5.49	29.07	15.15
	D (P29 D)	0.49	9.57	5.71	15.53	5.35
	Aq (P29 Aq)	0.72	89.29	8.69	9.70	1.50
<i>*Piper stellipilum</i>	H (P30H)	≤ 1	ND	ND	11.89	14.75
	D (P30D)	1.34	ND	ND	6.66	1.87
	M (P30M)	3.04	ND	ND	3.29	1.90
<i>*Piper trigonum</i>	H (P31H)	≤ 1	ND	ND	ND	11.31
	D (P31D)	0.31	ND	ND	ND	6.30
	M (P31M)	≤ 1	ND	ND	ND	9.15
<i>Piper verruculosum</i>	H (P32H)	≤ 1	ND	ND	ND	11.70
	D (P32D)	≤ 1	ND	ND	ND	17.73
	M (P32M)	≤ 1	ND	ND	ND	3.65
<i>Piper xanthostachyum</i>	H (P33H)	≤ 1	8.99	5.42	10.47	7.14
	D (P33D)	0.98	3.40	3.33	9.56	2.75
	HA (P33HA)	0.50	2.48	2.93	2.14	12.13

365 Antimicrobial activity

366 Antimicrobial assay results are presented in **Table 3** (17 Gram-positive bacteria, 13 Gram-negative
367 bacteria, 2 yeasts). Extracts were more active on Gram-positive bacteria and yeast. The IC₅₀ cut-off
368 values were set at ≤ 0.5 mg/mL for good activity and ≤ 0.09 mg/mL for very good activity. Among the
369 very active extracts, methylene chloride extract of *P. strigosum* is the most representative, being very
370 active on all Gram-positive strains [(excepted: *Staphylococcus warneri* (T26A1)], only on two Gram-
371 negative strains [(*Stenotrophomonas maltophilia* (21170) and *Burkholderia cepacia* (13003)], and on

372 the two *Candida albicans* strains. This extract was also quite active on *Streptococcus pyogenes*
 373 (16135). Other extracts with good activity on Gram-positive bacteria can be pointed out: methylene
 374 chloride extracts of *P. xantochyma* and *P. brasiliense*, and hydroalcoholic extract of *P. xantochyma*.
 375 Extracts with very good activity on Gram-negative bacteria are: methylene chloride extracts of *P.*
 376 *xantochyma* and *P. divaricatum* on *Burkholderia cepacia* (13003) and *Pseudomonas aeruginosa*
 377 (ATCC 27583), respectively. Extracts with very good activity on *Candida* strains were methylene
 378 chloride extracts of *P. pseudoaraboreum*, *P. divaricatum*, and *P. heterophyllum* and hexane extract of
 379 *P. sancti-felicitis*. Extracts with good activity on Gram-positive bacteria and *Candida* were principally
 380 methylene chloride of *P. brasiliense* and a hydroalcoholic extract of *P. xantochyma*.

Table 3. *In vitro* antimicrobial activity of *Piper* extracts (minimal inhibitory concentration MIC), in mg/mL). ND = not determinate, NA = not active.

Species / Type of extract	Extracts																				
		<i>Salmonella</i> sp. (1103)	<i>Pseudomonas aeruginosa</i> (8129)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	<i>Pseudomonas aeruginosa</i> (ATCC 27583)	
<i>Piper casapiense</i> (#4)	M	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	1.2	0.3	0.3	1.2	-	1.2	-	1.2	-	1.2	-	1.2	-	1.2	-	1.2	-	1.2	-	
	H	-	-	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper strigosum</i> (#12)	M	-	1.2	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	0.0375	
	H	0.6	0.15	0.0375	0.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper pseudoarboresum</i> (#14)	M	-	1.2	1.2	-	-	1.2	1.2	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	
	D	0.075	1.2	0.3	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.15	
	H	0.3	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper armatum</i> (#18)	M	-	0.3	0.6	-	-	1.2	1.2	1.2	1.2	1.2	0.6	1.2	1.2	1.2	1.2	1.2	1.2	1.2	0.3	
	D	0.6	0.3	0.075	0.6	1.2	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	1.2	
	H	0.3	-	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	
<i>Piper brasiliense</i> (#19)	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	0.15	0.15	0.15	0.3	-	0.3	0.3	0.3	0.3	0.3	0.15	0.15	0.3	1.2	0.6	0.3	0.3	0.3	0.3	
	H	0.3	-	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper bullatum</i> (#20)	M	-	0.3	0.3	-	-	1.2	0.6	1.2	0.6	0.6	0.3	0.3	0.6	0.3	0.6	0.3	-	-	-	
	D	-	-	0.3	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.3	
	H	0.15	0.6	0.075	0.3	-	0.6	0.6	0.6	0.6	0.6	1.2	0.6	0.6	0.3	0.6	0.15	0.075	0.15	-	
<i>Piper calvescentinerve</i> (#21)	M	-	0.6	-	-	-	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	0.6	
	D	0.3	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
	H	0.15	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper « cordatamentosa »</i> (#22)	M	-	0.6	-	-	-	1.2	1.2	1.2	1.2	1.2	0.6	0.6	1.2	1.2	1.2	1.2	1.2	1.2	0.6	
	D	0.6	-	0.6	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	
	H	0.3	-	0.3	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper crassinervium</i> (#23)	M	-	0.6	1.2	-	-	1.2	-	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	0.6	
	D	0.3	0.15	0.6	0.15	-	0.3	0.3	0.3	0.3	0.15	0.3	0.3	0.3	0.15	0.15	0.15	0.15	0.15	1.2	
	H	0.15	-	0.3	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	
<i>Piper divaricatum</i> (#24)	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	0.075	1.2	0.3	0.6	-	-	-	-	-	1.2	1.2	1.2	-	0.6	-	0.3	-	-	0.075	
	H	1.2	-	0.3	1.2	-	-	-	-	-	0.6	1.2	-	1.2	1.2	0.6	0.3	1.2	-	-	
<i>Piper glabribaccum</i> (#25)	M	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
	D	-	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
	H	0.15	-	0.3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper heterophyllum</i> (#26)	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	0.075	0.6	0.3	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
	H	-	-	0.6	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper oblongum</i> (#27)	M	1.2	0.3	0.6	-	-	1.2	1.2	0.6	0.6	0.6	0.6	0.6	0.3	0.3	1.2	0.6	0.6	-	0.3	
	D	1.2	0.6	0.3	0.6	1.2	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.3	-	1.2	
	H	0.15	0.6	0.15	0.3	-	0.6	0.6	0.6	0.3	0.3	0.3	0.3	0.15	0.3	0.15	0.3	0.3	0.3	-	
<i>Piper reticulatum</i> (#28)	M	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
	D	0.3	1.2	0.6	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	
	H	0.3	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.6	
<i>Piper sancti-felices</i> (#29)	Aq	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	D	0.3	1.2	0.3	1.2	-	-	-	-	-	1.2	1.2	1.2	-	1.2	-	0.3	1.2	-	1.2	
	H	0.075	1.2	0.3	1.2	-	-	-	-	-	0.6	0.6	-	0.6	0.6	0.075	-	1.2	0.6	-	
<i>Piper stellipilum</i> (#30)	M	-	0.3	-	-	1.2	0.6	-	0.6	0.6	0.6	0.3	0.3	0.3	0.3	1.2	0.6	0.3	0.3	0.3	
	D	1.2	-	0.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	H	0.3	1.2	1.2	0.6	-	0.6	1.2	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	
<i>Piper trigonum</i> (#31)	M	-	0.6	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.2	
	D	1.2	1.2	0.3	1.2	-	1.2	-	1.2	1.2	1.2	-	-	-	-	-	-	-	-	0.6	
	H	-	-	1.2	-	-	1.2	1.2	1.2	-	0.3	0.3	-	1.2	-	-	-	-	-	-	
<i>Piper verruculosum</i> (#32)	M	-	0.3	0.3	-	-	1.2	0.6	0.6	0.6	0.6	0.3	0.6	0.6	0.3	0.3	0.6	0.3	1.2	0.6	
	D	0.3	0.6	0.6	1.2	-	-	1.2	-	1.2	1.2	-	1.2	1.2	1.2	1.5	0.6	-	0.6	-	
	H	0.6	-	1.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
<i>Piper xanthostachyum</i> (#33)	HA	0.3	0.15	0.15	0.3	0.6	0.15	0.3	0.15	0.3	0.15	0.3	0.15	0.3	-	0.15	0.15	0.3	0.15	0.6	
	D	0.15	0.075	0.075	0.075	0.3	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.6	
	H	-	-	1.2	1.2	-	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	0.3	
Gentamycin	ND	ND	0.03	4	-	0.5	0.5	0.25	0.5	0.5	0.25	0.06	0.06	0.06	2	1	0.125	0.03	0.25	0.25	
Vancomycin	ND	ND	0.5	0.5	4	2	2	2	2	2	2	2	2	2	2	2	0.5	0.5	0.25	1	
Amoxicillin	ND	ND	2	64	2	4	16	0.125	16	1	8	16	1	0.25	0.25	0.06	0.03	0.25	0.25	2	
Amphotericin B	4	0.5	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Fluconazole	32	8	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	
Sertaconazole	NA	64	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	

LCMS data mining and statistical correlation analysis

After the application MS-CleanR workflow to the LCMS data, we obtained 123 unique metabolite features ($m/z \times RT \times$ Peak area). Among these, 56 compounds were annotated at the genus level (45.53 %), 6 compounds at the family level (4.88 %), and 55 compounds at the generic level (44.72 %), leaving 6 compounds unannotated (4.88 %). The MSMS fragmentation pathway of these compounds was used to establish a molecular network (**Figure 1**). Using NPClassifier and ClassyFire (Djoumbou Feunang et al., 2016; Kim et al., 2021), major phytochemical classes and subclasses of compounds were identified. The main classes of compounds identified were alkaloids, amino acids, fatty acids, polyketides, shikimates, phenylpropanoids, and terpenoids (metadata in **supp info 2**).




Figure 1. Molecular networking of putative compounds. A feature ID is allocated in each node. The colors in the network and pie chart relate to the phytochemical classes. The number of features for each class is also shown in the pie chart.

A heatmap of correlation analysis (Clustered Image Map, CIM) is shown in **Figure 2-A**. For this analysis, we compiled all *in vitro* assay results (30 bacterial strains, 2 fungal strains, 4 parasitic strains and 2 cell lines, **Tables 1** and **3**) versus the LCMS features. This figure results from a setting of the threshold of correlation at 0.3 (the heatmap is shown *in extenso* in **supp info 3**). Two groups of features responsible for activities can be distinguished. **Group 1** is composed of 11 features (12, 21, 23, 27, 31, 35, 41, 45, 87, 95, and 119) having activity on 21 bacteria, one fungus (*C. albicans* ATCC 10231), and one parasite (*T. b. gambiense*). Activity on bacteria was mostly concentrated on Gram-positive strains [(except for *Burkholderia cepacia* (13003), *Stenotrophomonas maltophilia* (21170), and the three

strains of *Escherichia coli*]]. **Group 2** is composed of 9 features (4, 6, 7, 16, 53, 63, 65, 77, and 117). This group was selective on *Leishmania* (all strains, both axenic and intramacrophagic). We also performed a relevance network (RN) analysis on the same datasets to verify and complete the CIM results (**Figure 2-B**). RN showed two main clusters of features linked to the activity, the same as in the CIM. The LC-MSMS molecular network (**Figure 1**) allowed to determine that six features identified in the **Group 1** belong to the alkaloids class, while others are mostly self-loops (*i. e.* compounds not having structurally-related analogs in the extract) belonging to varied phytochemical classes. In the case of *Leishmania*-specific compounds (**Group 2**), they mostly belong to the polyketides or shikimates and phenylpropanoids classes, and are found only as self-loops or only related to one compound and not correlated to any activity (*i.e.* features 16 and 4).




Figure 2. A) Clustered Image Map (CIM) performed on the two-blocks of data sets. The plot depicts the correlation between X = LCMS features (p = peak) data and Y = bioassays. Variables were selected across two dimensions and clustered with a complete Euclidean distance method. Blue squares represent the two main groups of features identified by activities B) The two main clusters of interaction represented by the relevance network (RN). The two analyses were tuned to a threshold of interaction of 0.3.

Table 4. Features identified as responsible for bioactivity. [†] = [M+H-H₂O]⁺; [‡] = [M+Na]⁺; [‡] = based on molecular networking.

Feature ID	m/z [M+H] ⁺	RT	Formula	Annotation	Annotation level	Phytochemical class
Group 1						
12	344.335	9.745	C ₂₄ H ₄₁ N	(1-{12,16-dimethylpentacyclooctadecan-15-yl}ethyl)dimethylamine	generic	terpenoid
21	362.342	9.745	C ₂₄ H ₄₃ NO	2,4,14-eicosatrienoic acid, 2-methylpropylamide	genus	fatty acids and conjugates

23	396.363	10.225	C ₂₃ H ₄₅ N ₃ O ₂	5-(4-aminobutyl)-1,5-diazacyclohenicosane-6,14-dione	generic	alkaloids and derivatives
27	337.573 [†]	10.391	C ₂₆ H ₄₇ NO	filifiline derivative	genus	alkaloids and derivatives [‡]
31	400.394 [†]	11.035		unknown		alkaloids and derivatives [‡]
35	428.426	11.628		unknown		alkaloids and derivatives [‡]
41	456.457	12.118		unknown		alkaloids and derivatives [‡]
45	489.155	10.287	C ₂₈ H ₂₄ O ₈	ferrudiol	genus	shikimates and phenylpropanoids
87	271.060	9.28	C ₁₅ H ₁₀ O ₅	apigenin	generic	shikimates and phenylpropanoids
95	279.232	10.707	C ₁₈ H ₃₀ O ₂	gamma-linolenate	generic	fatty acids and conjugates
119	316.301	9.077	C ₂₂ H ₃₇ N	daphnane	generic	alkaloids and derivatives
Group 2						
4	151.0755	6.5	C ₉ H ₁₀ O ₂	acetanisoole derivative	genus	shikimates and phenylpropanoids
6	221.081 [¥]	8.087	C ₁₀ H ₁₄ O ₄	decastrictin H	generic	polyketides
7	340.116 [¥]	7.486	C ₁₇ H ₁₉ NO ₅	aduncamide	genus	shikimates and phenylpropanoids
16	355.118	9.49	C ₂₀ H ₁₈ O ₆	sesamin	genus	shikimates and phenylpropanoids
53	593.277 [¥]	13.09	C ₃₂ H ₄₂ O ₉	swietenin E	generic	terpenoids
63	627.246	12.539	C ₃₃ H ₃₈ O ₁₂	thielavin L	generic	polyketides
65	197.117	6.022	C ₁₁ H ₁₆ O ₃	isololiolide	family	terpenoids
77	221.081	7.516	C ₁₀ H ₁₄ O ₄	modiolide A	generic	polyketides
117	312.159	8.705	C ₁₉ H ₂₁ NO ₃	piperettine	genus	alkaloids and derivatives

424

425 **Figure 3** shows a heatmap depicting how the features are distributed among the extracts. Features of
 426 **Group 1** are mainly distributed in all extracts of *P. strigosum* (features 12, 21, 23, 31, 41, 27 and 35)
 427 and *P. xanthostachyum* (features 45 and 87). Features of **Group 2** are found in the hexane and
 428 methylene chloride extracts of *P. sancti-felicis* and hexane extracts of *P. calvescentinerve*, *P.*
 429 *cordatomentosa* and *P. crassinervium* (features 6, 7, 16 and 77), methylene chloride extracts of *P.*
 430 *pseudoarboreum*, *P. calvescentinerve*, *P. divaricatum*, *P. glabribaccum*, *P. bullatum*, *P.*
 431 *heterophyllum*, *P. reticulatum*, *P. oblongum*, *P. trigonum*, *P. crassinervium* and *P. cordatomentosa*,
 432 and the aqueous extract of *P. sancti-felicis* (features 4, 53, 63, 65 and 117). Feature 95 is found in the
 433 methanol and hexane extracts of *P. reticulatum* and the hexane extracts of *P. pseudoarboreum*, *P.*
 434 *armatum*, *P. glabribaccum*, *P. oblongum* and *P. verruculosum*.

435




Figure 3. Heatmap of correlation between plant extracts and presumed bioactive peak features. Y = *Piper* extracts, and X = features of LC-MSMS analysis as shown in Figure 2A-B. Green and yellow squares represent the distribution of the bioactive features identified for the **Groups 1** and **2** in the *Piper* extracts.

DISCUSSION

Plants from the *Piper* genus are currently used by the Amerindian communities in Peru in different preparations (infusion of different parts, juice directly ingested, cataplasms made of crushed leaves or stems, etc.) to treat different diseases (Odonne et al., 2009, 2011; Vásquez-Ocmín et al., 2021a). For the present study, we conducted ethnopharmacological surveys in Loreto and Cusco, Peruvian Amazonian regions heavily impacted by protozoal diseases. Indeed, Loreto has always been the department with the greatest number of malaria cases (principally *P. vivax*), mostly affecting children from birth to age 11 (84.5 % in 2020) (Ministerio de Salud del Perú, 2021). Leishmaniasis occurrence in Peru is principally due to cutaneous (*L. amazonensis*, 17 892 cases over the last five years) and mucosal forms (*L. braziliensis*, *L. peruviana*, *L. lainsoni*, *L. guyanensis*, 1 642 cases in the last five years). To date, in 2022 70% of the cases of both forms were concentrated in 7 departments: Madre de Dios, Cusco (Echarate and Kosñipata districts), Piura, Junín, Loreto, Cajamarca and San Martín (Ministerio de Salud del Perú, 2022). In Peru, plant-based treatments are very common and even recommended by the health personnel. It is estimated that approximately 5000 species are used in the traditional medicine (Vásquez-Ocmín et al., 2018) among which the *Piper* species studied in this work represent 0.34 %. We targeted the ethnopharmacological survey on “*Cordoncillos*” (little cords), a word used to describe pepper vines in Amazonia because the presence of nodes on the stems reminds us of a *nudo de sogá* (node of cord). While this terminology would initially direct the sample collection, we took great care of properly identifying the species upon collection. In two cases, we could not fully ascertain the species and further taxonomic examination is underway.

Chemical profiling of natural extracts can be readily obtained, but for metabolomic purposes, data need to be ‘preprocessed’ (peak picking, alignment, clustering, integration and normalization) to obtain a clean dataset able to provide meaningful information upon statistical analysis. The large abundance and complexity of variables are also challenging and require to apply an appropriate statistical method to answer a specific biological question (Hervé et al., 2018). Few metabolomic studies on *Piper* species using NMR (Yamaguchi et al., 2011; Uckele et al., 2021) or LCMS have been reported so far (Vásquez-Ocmín et al., 2021a). The *Piper* genus is a good model to apply our framework for two reasons: i) *Piper* species are particularly abundant in Peru (~260 according to www.tropicos.org), many of them used in traditional medicine; ii) many studies, including numerous phytochemical ones, were carried out on this genus (~9000 results found in www.webofscience.com for “*Piper*”, consulted on July 1st, 2022), allowing a good metabolome coverage.

We propose in this work a computational statistical analysis to integrate two heterodimensional datasets: the features (compounds) obtained by LC-MSMS analysis of *Piper* extracts (**supp info 2**), and the *in vitro* biological activity of these extracts on parasites, bacteria and mammalian cells (**Tables 1 and 3**), with the aim to outline most active compounds. To leverage on this multiplexed approach, we applied a regularized Canonical Correlation Analysis (rCCA). This method aims to extract correlated information by maximizing their correlation via canonical variates between two datasets acquired on the same samples (vertical integration). The results of rCCA model were displayed using Clustered Image Maps (CIM) to highlight the correlation level of variables from all datasets, ordered through unsupervised clustering on both samples and compounds simultaneously (González et al., 2012). Another approach for displaying net-like correlation structures between two data sets is to use Relevance Networks (RN). This method generates a graph where nodes represent variables, and edges represent variable associations (Butte et al., 2000). Given an appropriate threshold, the RN highlights main correlation between both datasets (**Figure 2-B**). To our knowledge, the implementation of this type of metabolomics framework aimed at identifying bioactive compounds has not been used so far. However, a study has been recently published using rCCA to combine multiparametric analysis of

adjuvanticity *in vivo* with immunological profiles *in vitro* (cytokines, chemokines, and growth factor secretion analyzed by flow cytometry) of a library of compounds derived from hot-water extracts of herbal medicines (Hioki et al., 2022).

Figure 2 strikingly shows that the antibacterial and antileishmanial activities are correlated with two distinct groups of compounds. This is by no means surprising as these organisms have significantly different physiological organization, leading to different drugs currently used against these infections. The species showing the most significant antibacterial activities are *P. strigosum* and *P. xanthostachyum*, and the species showing the most significant antileishmanial activities are *P. pseudoarboresum*, *P. calvescentinerve*, *P. glabribaccum*, *P. reticulatum* and *P. sancti-felicitis*. The compounds correlated with these activities within these extracts are rather specific to these species (**Figure 3**). An overall weak activity of these *Piper* extracts on *P. falciparum* (**Table 1**) is an unexpected result, as *Piper* species are usually reputed for their antimalarial potential.

Features from **Group 1** were active not only on bacteria but also on one fungus and one parasite. Although the high cross-activity observed for this group of compounds (**Figure 2** and **supp info 3**) could foretell of a lack of selectivity, these compounds did not cause cytotoxicity in mammalian cells. Six of the features of **Group 1** annotated as alkaloid derivatives were grouped in a same cluster in the molecular networking (MN), suggesting a similar biosynthesis pathway. Only three of them were annotated in our workflow, suggesting that the three unannotated ones may have an original structure. The reliability of the annotation or classification (NPClassifire and ClassyFire) part of the workflow may nevertheless be tempered, as shown by the case of feature 27, classified by the workflow as an alkaloid, but annotated as filifline, a fatty amide previously isolated from the roots of *P. retrofractum* (Banerji et al., 2002). The broad bioactivity spectrum of alkaloids is well known, *i.e.*, antibacterial, antiparasitic, anticancer, but also their cytotoxicity (Newman and Cragg, 2007, 2020; Daley and Cordell, 2021; Yan et al., 2021). The mechanism of action of antibacterial alkaloids is mainly described as disrupting the bacterial membrane, affecting DNA function and inhibiting protein synthesis (Ananthan et al., 2009; Pan et al., 2014; Kelley et al., 2013; Li et al., 2014; Larghi et al.). Antibacterial alkaloids (MIC <10 µM/mL) are as diverse as isoquinolines, aporphines, phenanthrenes, quinolines and indoles and their activity is mostly oriented against Gram-positive bacteria (Porras et al., 2021). Quinoleines like 8-hydroxyquinoline and its derivatives and evocarpine are active on bacteria associated with respiratory system infections: *M. tuberculosis*, *S. aureus*, and MRSA (Methicillin-resistant *Staphylococcus aureus*) (MIC ≤ 10 µM/mL). Aporphine alkaloid derivatives exhibit high broad-spectrum activity against Gram-positive bacteria: *S. agalactiae*, *S. aureus*, *S. epidermidis*, *E. faecalis*, and as in our study *E. coli* (Hamoud et al., 2015; Tan et al., 2015). Even if the chemical array within *Piper* spp. is impressively diverse, nitrogen-containing compounds are limited, *i.e.*, alkaloids like piperines or amides like piplartine, phenethyls, and diaminodiamides. Amides are known to have fungicidal, cytotoxic, or antiprotozoal activities. With regard to fungicidal activity, dehydropipernonaline and nigramide R previously isolated from *P. retrofractum* displayed potent growth inhibition of *Cladosporium cladosporioides* and cytotoxicity against the L5178Y mouse lymphoma cell line (IC₅₀ values of 8.9 µM and 9.3 µM, respectively) (Muharini et al., 2015). Amide piplartine isolated from a methanol extract of *P. retrofractum* showed good activity on *L. donovani* with an IC₅₀ value at 7.5 µM (Bodiwala et al., 2007). In **Group 1**, features correlated with a fungicidal activity would only target *C. albicans*. Other active compounds identified in **Group 1** were one terpenoid, two fatty acids, one shikimate and phenylpropanoid derivative and one polyketide.

Compounds from the **Group 2**, characterized as being rather specific to *Leishmania*, are labeled as polyketides (3), shikimates and phenylpropanoids (3), terpenoids (2) and alkaloids (1). Their lack of activity on *Trypanosoma* is not surprising (**Figure 2**), as even though both parasites belong to the same

Trypanosomatidae order, the current treatments are not similar. These two parasites cause different pathologies, in distinct geographical areas. They evolved differently and show evolutionary discrepancies in their mechanisms that may explain variations in sensitivity to treatments (Fernandes et al., 2020; Van den Broeck et al., 2020). A cross-reading of **Figures 2 and 3**, suggests that extracts of *P. calvescentinerve* and *P. glabribaccum* and features from **Group 2** have not only a selectivity for *Leishmania* but also a good selectivity index. Selectivity is a key parameter for antileishmanial drugs: antimonials, amphotericin B, paromomycin sulfate and miltefosine have variable efficacy against the 20+ *Leishmania* species but have significant adverse effects (Rao et al., 2019). Tremendous efforts have been put into the understanding of the *Leishmania* biology, leading to the identification of numerous putative targets: ergosterol and its biosynthetic pathway [*i.e.* amphotericin B and enzymes like squalene synthase (SQS) or sterol methyltransferase (SMT)], the glycolytic pathway necessary to provide glucose as an energy source, DNA topoisomerases, enzymes of the polyamine biosynthetic pathway (*i.e.* arginase, ornithine decarboxylase, s-adenosylmethionine decarboxylase, and spermidine synthase), redox metabolism pathway (Nagle et al., 2014; Raj et al., 2020).

The compounds labeled as shikimates or phenylpropanoids (acetanisol, aduncamide, and sesamin) or alkaloid (piperettine) were annotated at the genus level because they had previously been isolated from *P. tuberculatum*, *P. nigrum*, *P. longum*, *P. aduncum*, *P. puberulum*, *P. austrosinense*, *P. brachystachyum*, *P. mullesua*, *P. retrofractum*, *P. sarmentosum* and *P. sylvaticum* (Spring and Stark, 1950; Orjala et al., 1993; De Araujo-Junior et al., 1997; Puri et al., 1998; Umezawa, 2003; Tuntiwachwuttikul et al., 2006). Among these compounds, only the lignan sesamin was reported to show activity on *L. amazonensis* with an IC_{50} of 44.6 μ M/mL and was not cytotoxic for mouse macrophage cells ($CC_{50} > 100$ μ g/mL, $SI > 6$) (Pulivarthi et al., 2015). A study based on computational methods suggests that sesamin could be a promising inhibitor of the *L. donovani* CRK12 receptor (binding affinity of -8.5 kcal/mol) (Broni et al., 2021). Nevertheless, sesamin, isolated from a hexane extract of *P. retrofractum* (IC_{50} of the extract = 5 μ g/mL), was inactive on *L. donovani* (Bodiwala et al., 2007) (Bodiwala et al., 2007). This compound was also inactive on *Plasmodium falciparum* K1 multidrug resistant strain, *Mycobacterium tuberculosis* H37Ra, and *Candida albicans* ($EC_{50} > 20$ μ g/mL, $MIC > 200$ μ g/mL and $IC_{50} > 50$ μ g/mL, respectively). Cubein, another lignan isolated from *P. cubeba*, was shown to be active on *L. donovani* ($IC_{50} = 28.0$ μ M). Interestingly, sesamin is connected in the MN with an unknown compound (RT = 6.577, $[M+H]^+ = 360.145$). Piperettine has been previously isolated from *P. nigrum* and *P. aurantiacum* and was shown to be active on epimastigotes and amastigotes of *Trypanosoma cruzi* ($IC_{50} = 10.67$ and 7.40 μ M, respectively) (Ribeiro et al., 2004). In our work, the compound annotated as piperettine was only detected in *P. calvescentinerve* extracts (**Figure 3**) but was not labeled as being correlated with any activity on *T. b. gambiense* (**supp info 3**). The use of this *Piper* species as a medicinal plant with various indications can partly be validated by the fact that it is an inhibitor of 5-lipoxygenase (76.02 μ M) (Muthuraman et al., 2019), a key enzyme involved in the biosynthesis of pro-inflammatory leukotrienes, provided its concentration is sufficient in the traditional preparations. Aduncamide was shown to present a moderate antineuroinflammatory activity (IC_{50} at 26 ± 8.3 μ M) by the Griess method on LPS-stimulated BV-2 cells (Zheng et al., 2021), to be cytotoxic for KB nasopharyngeal carcinoma cells ($ED_{50} = 5.7$ μ g/mL) and to inhibit growth Gram-positive *B. subtilis* and *M. luteus*, while being less active towards Gram-negative *E. coli* (Orjala et al., 1993). In our work, the compound annotated as aduncamide was identified in extracts of *P. glabribaccum*, *P. calvescentinerve* and *P. cordatomentosa*, whose extracts are among the most active on *Leishmania*. Two compounds were labeled as 10-membered lactone macrolides and annotated as decarestrictin H and modiolide A, previously isolated from the fungi *Penicillium simplicissimum* and *Stagonospora cirsii*, respectively (Grabley et al., 1992; Evidente et al., 2008). These two last annotations, although resulting from similar fragmentation patterns, may be subject to caution. Indeed, these compounds were annotated at the generic level and no macrolide has been identified in *Piper*

spp. so far (only a macrolactam, laevicarpin, previously isolated from *P. laevicarpus*) (da Silva A. Maciel et al., 2016). Furthermore, macrolides are well-known antibacterial compounds and thus should logically rather be clustered in **Group 1**, if ever present in the extracts. A compound annotated as apigenin was detected only in *P. xanthostachyum* and was identified as being correlated to the antibacterial activity (**Figure 2A**). This may appear surprising given that apigenin is a common and ubiquitous flavonoid with no antibacterial activity. The number of possible flavonoid isomers being quite large, this annotation may also be subject to caution, notwithstanding the fact that the actual compound (p87) being present in the extract remains of interest from the antibacterial perspective. Other compounds were annotated as flavonoids in the extracts (most of the compounds in **Group 3**, see **supp info 3**), characterized by a moderate activity of the extracts containing them, a moderate correlation with all the activities without any clear selectivity. These compounds were annotated at the genus level, as they were previously isolated from *Piper* species (Matsui and Munakata, 1976; Lago et al., 2004; González et al., 2022). Antiprotozoal or antimicrobial activity of flavonoids is well documented (Graf et al., 2005; Ortiz et al., 2017, 2020). Two compounds were annotated as pinocembrine and pinostrobin, both belonging to the flavanones subclass. Pinocembrine displays antifungal (*C. cladosporioides* and *C. sphaerospermum*) or antibacterial (*Enterococcus faecalis*, *Mycobacterium tuberculosis*) potential (Lago et al., 2004; Jeong et al., 2009; Gröblacher et al., 2012), while showing either no cytotoxicity on healthy and cancerous cell lines (RAW 264.7, epidermoid carcinoma of the oral cavity (KB), human small cell lung cancer (NCI-H187), metastatic murine colon 26-L5 carcinoma, PANC-1 human pancreatic cancer, metastatic human HT-1080 fibrosarcoma), or high cytotoxicity (Awale et al., 2009; Yenjai and Wanich, 2010; Lee et al., 2013). Pinostrobin showed weak antimalaria activity on *P. falciparum* (Kaur et al., 2009) but significant potential as a cancer chemopreventive agent (Gu et al., 2002).

Some of these *Piper* compounds are therefore of interest in an isolation and factual testing perspective. Compounds annotated as aduncamide, sesamin, and apigenin, along with the unknown compounds correlated to the activity, could be subjected to mass-targeted isolation (Vásquez-Ocmín et al., 2022a), in order to confirm their annotation or identify their structure, as well as confirm their biological potential.

CONCLUSION

Hyphenated analytical techniques are very useful to provide highly informative chemical profiling of complex metabolomes. Nevertheless, deciphering such profiles to determine the compounds responsible for the biological activity remains a challenge. By correlating these chemical profiles with biological assay results, we propose a workflow of integrated metabolomics statistical tools to provide a broad picture of the metabolome as well as a map of compounds putatively associated to the bioactivity. The structure of these compounds can either be annotated from previous works or remain unknown at this stage, but in any case, they require a formal isolation step to confirm their structure and activity. Nevertheless, an initial data mining on analytical-scale data proves very effective for prioritizing the compounds to target. The relevance of our approach has been validated on a set of *Piper* species tested for their anti-infectious diseases at the extract level. Such an approach can be extended to any type of natural extract, particularly when prior phytochemical data is available in the literature.

DATA AVAILABILITY STATEMENT

624 The raw data from the LCMS were uploaded to zenodo (DOI:10.5281/zenodo.7317966).

625 AUTHOR CONTRIBUTIONS

626 Conceptualization: PGVO, AM, GM, and LRM; Methodology: PGVO, AM, GM, and LRM; Chemical
627 data acquisition/curation: PGVO, KL, GM, AG, and AM; Statistical analysis: PGVO and GM;
628 Biological data curation: SC, VR, SB, and SP; Investigation: PGVO, SC, VR, GM, SP, AG, KL, ID,
629 LRV, HRC, WRM, KL, SB, LRM, and AM. PGVO wrote the original draft and all the authors
630 contributed to the final manuscript.

631 FUNDING

632 Authors acknowledge the funding support of the *Universidad Nacional de la Amazonia Peruana*
633 (UNAP) (Resolución Rectoral N°1312-2020-UNAP, 9/12/2020) and Financial support from the
634 French National Infrastructure for Metabolomics and Fluxomics, Grant MetaboHUB-ANR-11-INBS-
635 0010.

636 ACKNOWLEDGMENTS

637 Authors are indebted to the communities cited in this work for their essential contribution in order to
638 spread their ancestral knowledge. The authors thank IRD the French National Research Institute for
639 Sustainable Development (IRD), UMR 152 PHARMADEV, IRD-UPS (Toulouse, France) for the post-
640 doctoral fellowship to PG V-O (contract number 04077858). The authors thank MINEDU (Ministerio
641 de Educación), Lima, Peru, convenio MINEDU-UNAP (Decreto Supremo 146-2020, EF/Resolución
642 Rectoral N°1312-2020-UNAP, 9/12/2020). We also appreciate the important collaboration of Juan
643 Celedonio Ruiz (Herbarium Amazonense (AMAZ) de la Universidad Nacional de la Amazonía
644 Peruana (UNAP), Iquitos, Perú). The authors are also grateful to Amélie Perez (MetaboHUB-
645 MetaToul-Agromix, LRSV, Auzeville-Tolosane), Guillaume Cabanac (IRIT, Toulouse), and Rizwana
646 Zaffaroullah (CNR du Paludisme, AP-HP, Hôpital Bichat - Claude Bernard, F-75018 Paris, France).

647 REFERENCES

- 648 Alarcon-Barrera, J. C., Kostidis, S., Ondo-Mendez, A., and Giera, M. (2022). Recent advances in
649 metabolomics analysis for early drug development. *Drug Discovery Today* 27, 1763–1773. doi:
650 10.1016/j.drudis.2022.02.018.
- 651 Awale, S., Miyamoto, T., Linn, T. Z., Li, F., Win, N. N., Tezuka, Y., et al. (2009). Cytotoxic
652 constituents of *Soymida febrifuga* from Myanmar. *J. Nat. Prod.* 72, 1631–1636. doi:
653 10.1021/np9003323.
- 654 Balaraman, K., Vieira, N. C., Moussa, F., Vacus, J., Cojean, S., Pomel, S., et al. (2015). *In vitro* and *in*
655 *vivo* antileishmanial properties of a 2-n-propylquinoline hydroxypropyl β -cyclodextrin
656 formulation and pharmacokinetics via intravenous route. *Biomedicine & Pharmacotherapy* 76,
657 127–133. doi: 10.1016/j.biopha.2015.10.028.
- 658 Banerji, A., Sarkar, M., Datta, R., Sengupta, P., and Abraham, K. (2002). Amides from *Piper*
659 *brachystachyum* and *Piper retrofractum*. *Phytochemistry* 59, 897–901. doi: 10.1016/S0031-
660 9422(01)00364-8.
- 661 Bocquet, L., Sahpaz, S., Bonneau, N., Beaufay, C., Mahieux, S., Samailie, J., et al. (2019). Phenolic
662 compounds from *Humulus lupulus* as natural antimicrobial products: New weapons in the fight

- 663 against methicillin resistant *Staphylococcus aureus*, *Leishmania mexicana* and *Trypanosoma*
664 *brucei* Strains. *Molecules* 24, E1024. doi: 10.3390/molecules24061024.
- 665 Bodiwala, H. S., Singh, G., Singh, R., Dey, C. S., Sharma, S. S., Bhutani, K. K., et al. (2007).
666 Antileishmanial amides and lignans from *Piper cubeba* and *Piper retrofractum*. *J Nat Med* 61,
667 418–421. doi: 10.1007/s11418-007-0159-2.
- 668 Broni, E., Kwofie, S. K., Asiedu, S. O., Miller, W. A., and Wilson, M. D. (2021). A molecular modeling
669 approach to identify potential antileishmanial compounds against the cell division cycle (cdc)-
670 2-related kinase 12 (CRK12) receptor of *Leishmania donovani*. *Biomolecules* 11, 458. doi:
671 10.3390/biom11030458.
- 672 Butte, A. J., Tamayo, P., Slonim, D., Golub, T. R., and Kohane, I. S. (2000). Discovering functional
673 relationships between RNA expression and chemotherapeutic susceptibility using relevance
674 networks. *Proceedings of the National Academy of Sciences* 97, 12182–12186. doi:
675 10.1073/pnas.220392197.
- 676 CLSI (2006). *Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically*,
677 *approved standard*. 7th ed. Available at: [https://infostore.saiglobal.com/en-us/standards/CLSI-](https://infostore.saiglobal.com/en-us/standards/CLSI-M7-A7-7ED-2006-357843_SAIG_CLSI_CLSI_815015/)
678 [M7-A7-7ED-2006-357843_SAIG_CLSI_CLSI_815015/](https://infostore.saiglobal.com/en-us/standards/CLSI-M7-A7-7ED-2006-357843_SAIG_CLSI_CLSI_815015/) [Accessed September 2, 2022].
- 679 da Silva A. Maciel, D., Freitas, V. P., Conserva, G. A. A., Alexandre, T. R., Purisco, S. U., Tempone,
680 A. G., et al. (2016). Bioactivity-guided isolation of laevicarpin, an antitrypanosomal and
681 anticryptococcal lactam from *Piper laevicarpu* (Piperaceae). *Fitoterapia* 111, 24–28. doi:
682 10.1016/j.fitote.2016.04.005.
- 683 Daley, S., and Cordell, G. A. (2021). Alkaloids in contemporary drug discovery to meet global disease
684 needs. *Molecules* 26, 3800. doi: 10.3390/molecules26133800.
- 685 De Araujo-Junior, J. X., Da-Cunha, E. V. L., Chaves, M. C. D. O., and Gray, A. I. (1997). Piperdardine,
686 a piperidine alkaloid from *Piper tuberculatum*. *Phytochemistry* 44, 559–561. doi:
687 10.1016/S0031-9422(96)00503-1.
- 688 Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., et al. (2016).
689 ClassyFire: automated chemical classification with a comprehensive, computable taxonomy.
690 *Journal of Cheminformatics* 8, 61. doi: 10.1186/s13321-016-0174-y.
- 691 Durant-Archibold, A. A., Santana, A. I., and Gupta, M. P. (2018). Ethnomedical uses and
692 pharmacological activities of most prevalent species of genus *Piper* in Panama: A review.
693 *Journal of Ethnopharmacology* 217, 63–82. doi: 10.1016/j.jep.2018.02.008.
- 694 Evidente, A., Cimmino, A., Berestetskiy, A., Andolfi, A., and Motta, A. (2008). Stagonolides G–I and
695 Modiolide A, nonenolides produced by *Stagonospora cirsii*, a potential mycoherbicide for
696 *Cirsium arvense*. *J. Nat. Prod.* 71, 1897–1901. doi: 10.1021/np800415w.
- 697 Fernandes, P. M., Kinkead, J., McNae, I. W., Vásquez-Valdivieso, M., Wear, M. A., Michels, P. A.
698 M., et al. (2020). Kinetic and structural studies of *Trypanosoma* and *Leishmania*
699 phosphofructokinases show evolutionary divergence and identify AMP as a switch regulating
700 glycolysis versus gluconeogenesis. *FEBS J* 287, 2847–2861. doi: 10.1111/febs.15177.
- 701 Fraiser-Vannier, O., Chervin, J., Cabanac, G., Puech, V., Fournier, S., Durand, V., et al. (2020). MS-
702 CleanR: A Feature-Filtering Workflow for Untargeted LC–MS Based Metabolomics. *Anal.*
703 *Chem.* 92, 9971–9981. doi: 10.1021/acs.analchem.0c01594.

- 704 González, A. S., Tellini, V. H. S., and Gutiérrez, D. M. B. (2022). Study of the dermal anti-
705 inflammatory, antioxidant, and analgesic activity of pinostrobin. *Heliyon* 8. doi:
706 10.1016/j.heliyon.2022.e10413.
- 707 González, I., Cao, K.-A. L., Davis, M. J., and Déjean, S. (2012). Visualising associations between
708 paired ‘omics’ data sets. *BioData Mining* 5, 19. doi: 10.1186/1756-0381-5-19.
- 709 González, I., Déjean, S., Martin, P. G. P., and Baccini, A. (2008). CCA: An R Package to Extend
710 Canonical Correlation Analysis. *Journal of Statistical Software* 23, 1–14. doi:
711 10.18637/jss.v023.i12.
- 712 Grabley, S., Hammann, P., Hütter, K., Kirsch, R., Kluge, H., Thiericke, R., et al. (1992). Secondary
713 metabolites by chemical screening. 20 decarestrictines, a new family of inhibitors of cholesterol
714 biosynthesis from *Penicillium*: III. Decarestrictines E to M. *J. Antibiot.* 45, 1176–1181. doi:
715 10.7164/antibiotics.45.1176.
- 716 Graf, B. A., Milbury, P. E., and Blumberg, J. B. (2005). Flavonols, flavones, flavanones, and human
717 health: epidemiological evidence. *J Med Food* 8, 281–290. doi: 10.1089/jmf.2005.8.281.
- 718 Gröblacher, B., Kunert, O., and Bucar, F. (2012). Compounds of *Alpinia katsumadai* as potential efflux
719 inhibitors in *Mycobacterium smegmatis*. *Bioorganic & Medicinal Chemistry* 20, 2701–2706.
720 doi: 10.1016/j.bmc.2012.02.039.
- 721 Gu, J.-Q., Park, E. J., Vigo, J. S., Graham, J. G., Fong, H. H. S., Pezzuto, J. M., et al. (2002). Activity-
722 guided isolation of constituents of *Renealmia nicolaioides* with the potential to induce the hase
723 II enzyme quinone reductase. *J. Nat. Prod.* 65, 1616–1620. doi: 10.1021/np020249p.
- 724 Hamoud, R., Reichling, J., and Wink, M. (2015). Synergistic antibacterial activity of the combination
725 of the alkaloid sanguinarine with EDTA and the antibiotic streptomycin against multidrug
726 resistant bacteria. *Journal of Pharmacy and Pharmacology* 67, 264–273. doi:
727 10.1111/jphp.12326.
- 728 Hervé, M. R., Nicolè, F., and Lê Cao, K.-A. (2018). Multivariate Analysis of Multiple Datasets: a
729 Practical Guide for Chemical Ecology. *J Chem Ecol* 44, 215–234. doi: 10.1007/s10886-018-
730 0932-6.
- 731 Hioki, K., Hayashi, T., Natsume-Kitatani, Y., Kobiyama, K., Temizoz, B., Negishi, H., et al. (2022).
732 Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants.
733 *Frontiers in Immunology* 13. Available at:
734 <https://www.frontiersin.org/articles/10.3389/fimmu.2022.847616> [Accessed September 7,
735 2022].
- 736 Jeong, K.-W., Lee, J.-Y., Kang, D.-I., Lee, J.-U., Shin, S. Y., and Kim, Y. (2009). Screening of
737 flavonoids as candidate antibiotics against *Enterococcus faecalis*. *J. Nat. Prod.* 72, 719–724.
738 doi: 10.1021/np800698d.
- 739 Kaur, K., Jain, M., Kaur, T., and Jain, R. (2009). Antimalarials from nature. *Bioorganic & Medicinal*
740 *Chemistry* 17, 3229–3256. doi: 10.1016/j.bmc.2009.02.050.
- 741 Kelley, C., Lu, S., Parhi, A., Kaul, M., Pilch, D. S., and LaVoie, E. J. (2013). Antimicrobial activity of
742 various 4- and 5-substituted 1-phenyl-naphthalenes. *European Journal of Medicinal Chemistry*
743 60, 395–409. doi: 10.1016/j.ejmech.2012.12.027.
- 744 Kim, H. W., Wang, M., Leber, C. A., Nothias, L.-F., Reher, R., Kang, K. B., et al. (2021). NPClassifier:
745 A deep neural network-based structural classification tool for natural products. *J. Nat. Prod.*
746 84, 2795–2807. doi: 10.1021/acs.jnatprod.1c00399.

- 747 Lago, J. H. G., Ramos, C. S., Casanova, D. C. C., Morandim, A. de A., Bergamo, D. C. B., Cavaleiro,
748 A. J., et al. (2004). Benzoic acid derivatives from *Piper* species and their fungitoxic activity
749 against *Cladosporium cladosporioides* and *C. sphaerospermum*. *J. Nat. Prod.* 67, 1783–1788.
750 doi: 10.1021/np030530j.
- 751 Lambros, C., and Vanderberg, J. P. (1979). Synchronization of *Plasmodium falciparum* erythrocytic
752 stages in culture. *J Parasitol* 65, 418–420. doi: .10.2307/3280287.
- 753 Larghi, E. L., Bracca, A. B. J., Aguilar, A. A. A., Heredia, D. A., Pergomet, J. L., Simonetti, S. O., et
754 al. Neocryptolepine: A promising indoloisoquinoline alkaloid with interesting biological
755 activity. Evaluation of the drug and its most relevant analogs. *Current Topics in Medicinal*
756 *Chemistry* 15, 1683–1707.
- 757 Le Cao, K.-A., Rohart, F., Gonzalez, I., Dejean, S., Gautier, B., Bartolo, F., et al. (2016). mixOmics:
758 Omics Data Integration Project. R package version 6.1.1. Available at: [https://CRAN.R-](https://CRAN.R-project.org/package=mixOmics)
759 [project.org/package=mixOmics](https://CRAN.R-project.org/package=mixOmics).
- 760 Lee, C., Lee, J. W., Jin, Q., Jang, D. S., Lee, S.-J., Lee, D., et al. (2013). Inhibitory constituents of the
761 heartwood of *Dalbergia odorifera* on nitric oxide production in RAW 264.7 macrophages.
762 *Bioorganic & Medicinal Chemistry Letters* 23, 4263–4266. doi: 10.1016/j.bmcl.2013.04.032.
- 763 Li, N., Tan, S., Cui, J., Guo, N., Wang, W., Zu, Y., et al. (2014). PA-1, a novel synthesized pyrrolizidine
764 alkaloid, inhibits the growth of *Escherichia coli* and *Staphylococcus aureus* by damaging the
765 cell membrane. *J Antibiot* 67, 689–696. doi: 10.1038/ja.2014.49.
- 766 Matsui, K., and Munakata, K. (1976). Four new neolignans from *Piper futokadzura*. *Tetrahedron*
767 *Letters* 17, 4371–4374. doi: 10.1016/0040-4039(76)80118-9.
- 768 Mgbeahuruike, E. E., Yrjönen, T., Vuorela, H., and Holm, Y. (2017). Bioactive compounds from
769 medicinal plants: Focus on *Piper* species. *South African Journal of Botany* 112, 54–69. doi:
770 10.1016/j.sajb.2017.05.007.
- 771 Ministerio de Salud del Perú (2021). Boletín Epidemiológico del Perú SE 02-2021. Available at:
772 [https://cdn.www.gob.pe/uploads/document/file/1865086/Bolet%C3%ADn%20epidemiol%C3](https://cdn.www.gob.pe/uploads/document/file/1865086/Bolet%C3%ADn%20epidemiol%C3%B3gico%20del%20Per%C3%BA%202021.pdf?v=1629922432)
773 [%B3gico%20del%20Per%C3%BA%202021.pdf?v=1629922432](https://cdn.www.gob.pe/uploads/document/file/1865086/Bolet%C3%ADn%20epidemiol%C3%B3gico%20del%20Per%C3%BA%202021.pdf?v=1629922432) [Accessed October 2, 2021].
- 774 Ministerio de Salud del Perú (2022). Boletín Epidemiológico del Perú-Situación epidemiológica de la
775 Leishmaniasis en el Perú SE 12-2022. Available at:
776 https://www.dge.gob.pe/epipublic/uploads/boletin/boletin_202212_22_181950_2.pdf
777 [Accessed October 2, 2021].
- 778 Muharini, R., Liu, Z., Lin, W., and Proksch, P. (2015). New amides from the fruits of *Piper*
779 *retrofractum*. *Tetrahedron Letters* 56, 2521–2525. doi: 10.1016/j.tetlet.2015.03.116.
- 780 Muthuraman, S., Sinha, S., Vasavi, C. S., Waidha, K. M., Basu, B., Munussami, P., et al. (2019).
781 Design, synthesis and identification of novel coumapherine derivatives for inhibition of human
782 5-LOX: Antioxidant, pseudoperoxidase and docking studies. *Bioorganic & Medicinal*
783 *Chemistry* 27, 604–619. doi: 10.1016/j.bmc.2018.12.043.
- 784 Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., et al. (2014).
785 Recent developments in drug discovery for Leishmaniasis and Human African
786 Trypanosomiasis. *Chem. Rev.* 114, 11305–11347. doi: 10.1021/cr500365f.
- 787 Newman, D. J., and Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25
788 years. *J. Nat. Prod.* 70, 461–477. doi: 10.1021/np068054v.

- 789 Newman, D. J., and Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly
790 four decades from 01/1981 to 09/2019. *J. Nat. Prod.* 83, 770–803. doi:
791 10.1021/acs.jnatprod.9b01285.
- 792 Olivon, F., Elie, N., Grelier, G., Roussi, F., Litaudon, M., and Touboul, D. (2018). MetGem software
793 for the generation of molecular networks based on the t-SNE algorithm. *Anal. Chem.* 90,
794 13900–13908. doi: 10.1021/acs.analchem.8b03099.
- 795 Orjala, J., Wright, A. D., Rali, T., and Sticher, O. (1993). Aduncamide, a cytotoxic and antibacterial b-
796 phenylethylamine-derived amide from *Piper aduncum*. *Natural Product Letters* 2, 231–236.
797 doi: 10.1080/10575639308043814.
- 798 Ortiz, S., Dali-Yahia, K., Vásquez-Ocmín, P., Grougnet, R., Grellier, P., Michel, S., et al. (2017).
799 Heme-binding activity of methoxyflavones from *Pentzia monodiana* Maire (Asteraceae).
800 *Fitoterapia* 118, 1–5. doi: 10.1016/j.fitote.2017.01.012.
- 801 Ortiz, S., Vásquez-Ocmín, P. G., Cojean, S., Bouzidi, C., Michel, S., Figadère, B., et al. (2020).
802 Correlation study on methoxylation pattern of flavonoids and their heme-targeted
803 antiplasmodial activity. *Bioorganic Chemistry* 104, 104243. doi:
804 10.1016/j.bioorg.2020.104243.
- 805 Pomel, S., Dubar, F., Forge, D., Loiseau, P. M., and Biot, C. (2015). New heterocyclic compounds:
806 Synthesis and antitrypanosomal properties. *Bioorg. Med. Chem* 23, 5168–5174. doi:
807 10.1016/j.bmc.2015.03.029.
- 808 Porras, G., Chassagne, F., Lyles, J. T., Marquez, L., Dettweiler, M., Salam, A. M., et al. (2021).
809 Ethnobotany and the role of plant natural products in antibiotic drug discovery. *Chem. Rev.*
810 121, 3495–3560. doi: 10.1021/acs.chemrev.0c00922.
- 811 Pulivarthi, D., Steinberg, K. M., Monzote, L., Piñón, A., and Setzer, W. N. (2015). Antileishmanial
812 activity of compounds isolated from *Sassafras albidum*. *Nat Prod Commun* 10, 1229–1230.
- 813 Puri, B., Hall, A., Harborne, J. B., Baxter, H., and Moss, G. P. (1998). “Lignans,” in *Phytochemical*
814 *Dictionary* (CRC Press).
- 815 Raj, S., Sasidharan, S., Balaji, S. N., and Saudagar, P. (2020). An overview of biochemically
816 characterized drug targets in metabolic pathways of *Leishmania* parasite. *Parasitol Res* 119,
817 2025–2037. doi: 10.1007/s00436-020-06736-x.
- 818 Rao, S. P. S., Barrett, M. P., Dranoff, G., Faraday, C. J., Gimpelewicz, C. R., Hailu, A., et al. (2019).
819 Drug discovery for Kinetoplastid diseases: Future directions. *ACS Infect. Dis.* 5, 152–157. doi:
820 10.1021/acsinfecdis.8b00298.
- 821 Ribeiro, T. S., Freire-de-Lima, L., Previato, J. O., Mendonça-Previato, L., Heise, N., and Freire de
822 Lima, M. E. (2004). Toxic effects of natural piperine and its derivatives on epimastigotes and
823 amastigotes of *Trypanosoma cruzi*. *Bioorganic & Medicinal Chemistry Letters* 14, 3555–3558.
824 doi: 10.1016/j.bmcl.2004.04.019.
- 825 Ruiz-Vásquez, L., Ruiz Mesia, L., Caballero Ceferino, H. D., Ruiz Mesia, W., Andrés, M. F., Díaz, C.
826 E., et al. (2022). Antifungal and herbicidal potential of *Piper* essential oils from the Peruvian
827 Amazonia. *Plants* 11, 1793. doi: 10.3390/plants11141793.
- 828 Salehi, B., Zakaria, Z. A., Gyawali, R., Ibrahim, S. A., Rajkovic, J., Shinwari, Z. K., et al. (2019). Piper
829 Species: A Comprehensive Review on Their Phytochemistry, Biological Activities and
830 Applications. *Molecules* 24, 1364. doi: 10.3390/molecules24071364.

- 831 SFE (2022). Ethnopharmacologie, plantes médicinales, médecine traditionnelle. *Société Française*
832 *d’Ethnopharmacologie*. Available at: <http://www.ethnopharmacologia.org/definition/>
833 [Accessed July 26, 2022].
- 834 Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., et al. (2003). Cytoscape:
835 A software environment for integrated models of biomolecular interaction networks. *Genome*
836 *Res.* 13, 2498–2504. doi: 10.1101/gr.1239303.
- 837 Spring, F. S., and Stark, J. (1950). Piperettine from *Piper nigrum*; its isolation, identification, and
838 synthesis. *J. Chem. Soc.*, 1177–1180. doi: 10.1039/JR9500001177.
- 839 Tan, K. K., Khoo, T. J., Rajagopal, M., and Wiart, C. (2015). Antibacterial alkaloids from *Artabotrys*
840 *crassifolius* Hook.f. & Thomson. *Natural Product Research* 29, 2346–2349. doi:
841 10.1080/14786419.2015.1013954.
- 842 Trager, W., and Jensen, J. B. (1976). Human malaria parasites in continuous culture. *Science* 193, 673–
843 675.
- 844 Trujillo, W., Trujillo, E. T., Ortiz-Morea, F. A., Toro, D. A., and Jaramillo, M. A. (2022). New *Piper*
845 species from the eastern slopes of the Andes in northern South America. *PhytoKeys* 206, 25–
846 48. doi: 10.3897/phytokeys.206.75971.
- 847 Tsugawa, H., Cajka, T., Kind, T., Ma, Y., Higgins, B., Ikeda, K., et al. (2015). MS-DIAL: data-
848 independent MS/MS deconvolution for comprehensive metabolome analysis. *Nature Methods*
849 12, 523–526. doi: 10.1038/nmeth.3393.
- 850 Tsugawa, H., Kind, T., Nakabayashi, R., Yukihiro, D., Tanaka, W., Cajka, T., et al. (2016). Hydrogen
851 rearrangement rules: Computational MS/MS fragmentation and structure elucidation using MS-
852 FINDER software. *Anal. Chem.* 88, 7946–7958. doi: 10.1021/acs.analchem.6b00770.
- 853 Tuntiwachwuttikul, P., Phansa, P., Pootaeng-on, Y., and Taylor, W. C. (2006). Chemical Constituents
854 of the Roots of *Piper Sarmentosum*. *Chemical and Pharmaceutical Bulletin* 54, 149–151. doi:
855 10.1248/cpb.54.149.
- 856 Uckele, K. A., Jahner, J. P., Tepe, E. J., Richards, L. A., Dyer, L. A., Ochsenrider, K. M., et al. (2021).
857 Phytochemistry reflects different evolutionary history in traditional classes versus specialized
858 structural motifs. *Sci Rep* 11, 17247. doi: 10.1038/s41598-021-96431-3.
- 859 Umezawa, T. (2003). Diversity in lignan biosynthesis. *Phytochemistry Reviews* 2, 371–390. doi:
860 10.1023/B:PHYT.0000045487.02836.32.
- 861 Van den Broeck, F., Savill, N. J., Imamura, H., Sanders, M., Maes, I., Cooper, S., et al. (2020).
862 Ecological divergence and hybridization of Neotropical *Leishmania* parasites. *Proc Natl Acad*
863 *Sci U S A* 117, 25159–25168. doi: 10.1073/pnas.1920136117.
- 864 Vásquez-Ocmín, P., Cojean, S., Rengifo, E., Suyyagh-Albouz, S., Amasifuen Guerra, C. A., Pomel,
865 S., et al. (2018). Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road
866 communities in Loreto (Peru). *Journal of Ethnopharmacology* 210, 372–385. doi:
867 10.1016/j.jep.2017.08.039.
- 868 Vásquez-Ocmín, P. G., Gadea, A., Cojean, S., Marti, G., Pomel, S., Van Baelen, A.-C., et al. (2021a).
869 Metabolomic approach of the antiprotozoal activity of medicinal *Piper* species used in Peruvian
870 Amazon. *Journal of Ethnopharmacology* 264, 113262. doi: 10.1016/j.jep.2020.113262.
- 871 Vásquez-Ocmín, P. G., Gallard, J.-F., Van Baelen, A.-C., Leblanc, K., Cojean, S., Mouray, E., et al.
872 (2022a). Biodereplication of Antiplasmodial Extracts: Application of the Amazonian Medicinal
873 Plant *Piper coruscans* Kunth. *Molecules* 27, 7638. doi: 10.3390/molecules27217638.

- 874 Vásquez-Ocmín, P. G., Marti, G., Bonhomme, M., Mathis, F., Fournier, S., Bertani, S., et al. (2021b).
875 Cannabinoids vs. whole metabolome: Relevance of cannabinomics in analyzing *Cannabis*
876 varieties. *Analytica Chimica Acta* 1184, 339020. doi: 10.1016/j.aca.2021.339020.
- 877 Vásquez-Ocmín, P. G., Marti, G., Gadea, A., Cabanac, G., Vásquez-Briones, J. A., Casavilca-
878 Zambrano, S., et al. (2022b). Metabotyping of Andean pseudocereals and characterization of
879 emerging mycotoxins. 2022.06.23.497323. doi: 10.1101/2022.06.23.497323.
- 880 Vásquez-Ocmín, P., Haddad, M., Gadea, A., Jullian, V., Castillo, D., Paloque, L., et al. (2017). A new
881 phthalide derivative from *Peperomia nivalis*. *Natural Product Research* 31, 138–142. doi:
882 10.1080/14786419.2016.1219857.
- 883 WHO (2021). World malaria report 2021. Available at: [https://www.who.int/teams/global-malaria-](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021)
884 [programme/reports/world-malaria-report-2021](https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021) [Accessed July 26, 2022].
- 885 WHO (2022a). Neglected tropical diseases. Available at: [https://www.who.int/health-topics/neglected-](https://www.who.int/health-topics/neglected-tropical-diseases)
886 [tropical-diseases](https://www.who.int/health-topics/neglected-tropical-diseases) [Accessed July 25, 2022].
- 887 WHO (2022b). The sustainable development goals. Available at:
888 <https://www.un.org/sustainabledevelopment/> [Accessed October 3, 2022].
- 889 Yamaguchi, L. F., Freitas, G. C., Yoshida, N. C., Silva, R. A., Gaia, A. M., Silva, A. M., et al. (2011).
890 Chemometric analysis of ESIMS and NMR data from *Piper* species. *J. Braz. Chem. Soc.* 22,
891 2371–2382. doi: 10.1590/S0103-50532011001200019.
- 892 Yan, Y., Li, X., Zhang, C., Lv, L., Gao, B., and Li, M. (2021). Research progress on antibacterial
893 activities and mechanisms of natural alkaloids: A review. *Antibiotics* 10, 318. doi:
894 10.3390/antibiotics10030318.
- 895 Yenjai, C., and Wanich, S. (2010). Cytotoxicity against KB and NCI-H187 cell lines of modified
896 flavonoids from *Kaempferia parviflora*. *Bioorganic & Medicinal Chemistry Letters* 20, 2821–
897 2823. doi: 10.1016/j.bmcl.2010.03.054.
- 898 Zheng, Y., Su, B., Wang, Y., Wang, H., Liao, H., and Liang, D. (2021). New tyramine- and aporphine-
899 type alkamides with NO release inhibitory activities from *Piper puberulum*. *J. Nat. Prod.* 84,
900 1316–1325. doi: 10.1021/acs.jnatprod.1c00055.
- 901